var title_f2_37_2640="Clubbing";
var content_f2_37_2640=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clubbing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clubbing of the fingers in a three-year old child with an endocardial cushion defect.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Clark DA. Atlas of Neonatology, WB Saunders, Philadelphia 2000. Copyright &copy; 2000 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_37_2640=[""].join("\n");
var outline_f2_37_2640=null;
var title_f2_37_2641="Smallpox vaccine: Patient drug information";
var content_f2_37_2641=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Smallpox vaccine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/24/18823?source=see_link\">",
"     see \"Smallpox vaccine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ACAM2000&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt adi-os drugH1Div\" id=\"F10026003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     CDC Information",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaccine Information Statements (VIS) are made by the staff of the Centers for Disease Control and Prevention (CDC). Each VIS gives information to properly inform the adult receiving the vaccine or, in the case of a minor, the child's parent or legal representative about the risks and benefits of each vaccine. Before a doctor vaccinates a child or an adult, the provider is required by the National Childhood Vaccine Injury Act to give a copy of the VIS. You can also get foreign language versions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2706006",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <a href=\"file://www.immunize.org/vis/vis_smallpox.asp%20%20\" target=\"_blank\">",
"        Vaccine Information Statements (VIS)",
"       </a>",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11913 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-E8883028DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_37_2641=[""].join("\n");
var outline_f2_37_2641=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221461\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026003\">",
"      CDC Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/24/18823?source=related_link\">",
"      Smallpox vaccine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_37_2642="Ultrasound acute cholecystitis and Mirizzi syndrome";
var content_f2_37_2642=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F86878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F86878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Ultrasound from a patient with acute cholecystitis and Mirizzi syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 223px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transabdominal ultrasound from a patient with acute cholecystitis and Mirizzi syndrome. The patient presented with right upper quadrant pain and jaundice. Acute cholecystitis and Mirizzi syndrome are confirmed by the ultrasound findings of a positive sonographic Murphy's sign (pain with compression of the gallbladder by the ultrasound probe), a large shadowing stone impacted in the infundibulum of the gallbladder (white arrow), cholestasis with sludge (yellow arrowhead), and a dilated common hepatic duct (white arrowheads in B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_37_2642=[""].join("\n");
var outline_f2_37_2642=null;
var title_f2_37_2643="Uremic mononeuropathy";
var content_f2_37_2643=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Uremic mononeuropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/37/2643/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/37/2643/contributors\">",
"     Biff F Palmer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/37/2643/contributors\">",
"     William L Henrich, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/37/2643/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/37/2643/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/37/2643/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/37/2643/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/37/2643/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high incidence of a systemic polyneuropathy in end-stage renal disease predisposes to the development of clinically apparent mononeuropathies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2643/abstract/1\">",
"     1",
"    </a>",
"    ]. The most commonly affected nerves are those in the forearm, particularly, the median and ulnar nerves. The typical presentation is that of the carpal tunnel syndrome. Multiple factors appear to be pathogenetically important, including direct compression, ischemia, and infiltration by amyloid fibrils composed of beta2-microglobulin. Other mononeuropathies in end stage renal disease may affect the seventh and eighth cranial nerves, the peroneal nerve, and the femoral nerve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CARPAL TUNNEL SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial symptoms of the carpal tunnel syndrome include numbness, tingling, and sometimes burning along the distribution of the median nerve in the hand [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2643/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients may also complain of paresthesias more proximally in the forearm. More advanced cases may be associated with atrophy of the proximal thenar muscle on physical examination. Tinel's sign refers to the ability to reproduce the numbness and tingling sensation by gently percussing the median nerve at the wrist. Electrophysiologic studies can confirm the diagnosis by demonstrating prolonged conduction for both motor and sensory fibers through the area of the carpal tunnel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;One distinctive feature of the carpal tunnel syndrome in end-stage renal disease is the tendency for symptoms to worsen during hemodialysis. As a result, it has been proposed the presence of a vascular access in the same arm may play a contributory role.",
"   </p>",
"   <p>",
"    The carpal tunnel, through which the median nerve passes, is narrow and bounded by the transverse carpal ligament superiorly and the carpal bones inferiorly. Given this narrow passageway, the median nerve is susceptible to injury by a number of factors which may be related to vascular access:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased venous pressure could result in extravasation of fluid, leading to extrinsic compression of the nerve [",
"      <a class=\"abstract\" href=\"UTD.htm?2/37/2643/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Compression could also be induced by bleeding from the access, with tracking of fluid along the fascial planes.",
"     </li>",
"     <li>",
"      A vascular steal phenomenon can lead to ischemic neural injury and nerve dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?2/37/2643/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, a banding procedure or even ligation of the access should be considered when signs or symptoms indicative of a peripheral neuropathy develop shortly after the creation of a vascular access.",
"   </p>",
"   <p>",
"    However, there is evidence that additional mechanisms, unrelated to vascular access, may contribute to the carpal tunnel syndrome in many patients. A electrophysiologic study in patients on chronic hemodialysis found that both subclinical median nerve dysfunction and the fully expressed carpal tunnel syndrome was independent of the side of the dialysis access [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2643/abstract/5\">",
"     5",
"    </a>",
"    ]. Furthermore, patients on peritoneal dialysis were found to have an incidence of median nerve dysfunction comparable to those on hemodialysis.",
"   </p>",
"   <p>",
"    One factor that may be important in this regard in patients on long-term dialysis is the local deposition of amyloid fibrils derived mostly from &szlig;-microglobulin. Findings suggestive of this diagnosis include the presence of pain in multiple joints of the upper and lower extremities (particularly the shoulders) and, on x-ray, radiolucencies in the carpal bones. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5609?source=see_link\">",
"     \"Dialysis-related amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OTHER MONONEUROPATHIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysfunction of both the vestibular and cochlear divisions of the eighth cranial nerve have been described in patients with chronic renal failure. In some of these cases, dysfunction can be attributed to direct ototoxicity from drugs (such as the aminoglycosides or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ) or to hereditary nephritis (which is frequently associated with deafness). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=see_link\">",
"     \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"    </a>",
"    .) However, no cause other than chronic renal failure is apparent in many cases. The most convincing evidence for the role of uremia comes from reports in which hearing impairment dramatically improved following intensive hemodialysis or renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2643/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Facial nerve dysfunction has also been described in chronic renal failure. The defect is largely subclinical, being detected only by electrophysiologic studies.",
"   </p>",
"   <p>",
"    Compressive neuropathies also may be seen, affecting the ulnar nerve and peroneal nerve. In one single center study, roughly one-half of patients undergoing maintenance dialysis had an ulnar neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2643/abstract/7\">",
"     7",
"    </a>",
"    ]. The underlying cause was unclear, although nerve ischemia may have been an underlying factor.",
"   </p>",
"   <p>",
"    Uremic patients are often malnourished prior to the initiation of dialysis. As a result, these nerves are more exposed at the elbow and fibular head, respectively, and are therefore more susceptible to direct compression.",
"   </p>",
"   <p>",
"    Mononeuropathy in end-stage renal disease can be a complication of vascular access. Thus, femoral nerve neuropathy may be a complication of femoral vein catheterization, while the radial nerve can be injured during a difficult cannulation of an arteriovenous fistula in preparation for hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2643/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Optic neuropathy has also been reported in patients with chronic renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2643/abstract/9\">",
"     9",
"    </a>",
"    ]. The pathogenesis of this lesion appears to be primarily ischemic rather than toxic in origin. Risk factors for the development of optic neuropathy include recurrent hypotension on dialysis, anemia, and generalized atherosclerosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H628697675\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with end-stage renal disease (ESRD) may develop clinically apparent mononeuropathies. The most commonly affected nerves are those in the forearm, particularly, the median and ulnar nerves. The typical presentation is that of the carpal tunnel syndrome. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial symptoms of the carpal tunnel syndrome in such patients include numbness, tingling, and sometimes burning along the distribution of the median nerve in the hand. Patients may also complain of paresthesias more proximally in the forearm. Symptoms may worsen during hemodialysis, possibly due to the presence of a vascular access in the same arm.",
"      <br/>",
"      <br/>",
"      Physical findings include a positive Tinel&rsquo;s sign and atrophy of the proximal thenar muscle in advanced cases. Electrophysiologic studies can confirm the diagnosis by demonstrating prolonged conduction for both motor and sensory fibers through the area of the carpal tunnel. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Carpal tunnel syndrome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The carpal tunnel syndrome in ESRD patients is due, in part, to injury to the median nerve by a number of factors related to vascular access. A banding procedure or ligation of the access should be considered when signs or symptoms indicative of a peripheral neuropathy develop shortly after the creation of a vascular access. Additional mechanisms, such as the deposition of amyloid fibrils derived from &szlig;-microglobulin, may also contribute to the carpal tunnel syndrome in many patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other mononeuropathies among ESRD patients may affect the seventh and eighth cranial nerves, the peroneal nerve, and the femoral nerve. In some of these cases, dysfunction can be attributed to direct ototoxicity from drugs (such as the aminoglycosides or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      ) or to hereditary nephritis. Mononeuropathy may also be a complication of vascular access (ie, femoral nerve neuropathy may be a complication of femoral vein catheterization, while the radial nerve can be injured during a difficult cannulation of an arteriovenous fistula in preparation for hemodialysis). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Overview'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Other mononeuropathies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2643/abstract/1\">",
"      Krishnan AV, Kiernan MC. Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve 2007; 35:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2643/abstract/2\">",
"      Reese, GN, Appel, SH. Neurologic complications of renal failure. Semin Nephrol 1981; 1:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2643/abstract/3\">",
"      Delmez JA, Holtmann B, Sicard GA, et al. Peripheral nerve entrapment syndromes in chronic hemodialysis patients. Nephron 1982; 30:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2643/abstract/4\">",
"      Kimura I, Sekino H, Ayyar DR, et al. Carpal tunnel syndrome in patients on long-term hemodialysis. Tohoku J Exp Med 1986; 148:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2643/abstract/5\">",
"      Bicknell JM, Lim AC, Raroque HG Jr, Tzamaloukas AH. Carpal tunnel syndrome, subclinical median mononeuropathy, and peripheral polyneuropathy: common early complications of chronic peritoneal dialysis and hemodialysis. Arch Phys Med Rehabil 1991; 72:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2643/abstract/6\">",
"      Anteunis LJ, Mooy JM. Hearing loss in a uraemic patient: indications of involvement of the VIIIth nerve. J Laryngol Otol 1987; 101:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2643/abstract/7\">",
"      Nardin R, Chapman KM, Raynor EM. Prevalence of ulnar neuropathy in patients receiving hemodialysis. Arch Neurol 2005; 62:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2643/abstract/8\">",
"      Kalita J, Misra UK, Sharma RK, Rai P. Femoral and radial neuropathy following vascular access cannulation for hemodialysis. Nephron 1995; 69:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2643/abstract/9\">",
"      Haider S, Astbury NJ, Hamilton DV. Optic neuropathy in uraemic patients on dialysis. Eye (Lond) 1993; 7 ( Pt 1):148.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1842 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-93025ABAAB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_37_2643=[""].join("\n");
var outline_f2_37_2643=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H628697675\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CARPAL TUNNEL SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OTHER MONONEUROPATHIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H628697675\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5609?source=related_link\">",
"      Dialysis-related amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=related_link\">",
"      Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_37_2644="Calculator: CDC weight for height percentiles for girls (77 to 121 cm tall)";
var content_f2_37_2644=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"CDCWeightForHeightGirls_form\" name=\"CDCWeightForHeightGirls_form\" onkeydown=\"clrResults();\" onkeypress=\"return validNumberField(event);\" onkeyup=\"CDCWeightForHeightGirls_fx();\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: CDC weight for height percentiles for girls (77 to 121 cm tall)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          ZScore = ((Weight/M)",
"          <sup>",
"           L",
"          </sup>",
"          - 1) / (L * S)",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Height",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Height_param\" onblur=\"CDCWeightForHeightGirls_fx(); minMaxCheck();\" onchange=\"CDCWeightForHeightGirls_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Height_unit\" onchange=\"CDCWeightForHeightGirls_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|cm\">",
"               cm",
"              </option>",
"              <option value=\"30.48|0|ft\">",
"               ft",
"              </option>",
"              <option value=\"2.54|0|in\">",
"               in",
"              </option>",
"              <option value=\"0.0001|0|micm\">",
"               micm",
"              </option>",
"              <option value=\"0.1|0|mm\">",
"               mm",
"              </option>",
"              <option value=\"100|0|m\">",
"               m",
"              </option>",
"              <option value=\"1e-07|0|nm\">",
"               nm",
"              </option>",
"              <option value=\"91.44|0|yd\">",
"               yd",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Weight",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Weight_param\" onblur=\"CDCWeightForHeightGirls_fx(); minMaxCheck();\" onchange=\"CDCWeightForHeightGirls_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Weight_unit\" onchange=\"CDCWeightForHeightGirls_fx();\" style=\"width:105px;\">",
"              <option value=\"0.001|0|gm\">",
"               gm",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|kg\">",
"               kg",
"              </option>",
"              <option value=\"0.45359237|0|lb\">",
"               lb",
"              </option>",
"              <option value=\"1e-06|0|mg\">",
"               mg",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Results:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Z Score",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Z_Score_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Percentile",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Percentile_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"CDCWeightForHeightGirls_fx();\">",
"              <option>",
"               0",
"              </option>",
"              <option selected=\"selected\">",
"               1",
"              </option>",
"              <option>",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"      <tr>",
"       <td bgcolor=\"#eeeeee\" width=\"1%\">",
"        <br/>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <span class=\"medCalcFontTitleBox\">",
"         Weight for Height Percentile Interpretation",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <center>",
"      <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"       <tr id=\"rr1_1\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"         <span class=\"medCalcFontOneBold\">",
"          Percentile &lt;5:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Underweight",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_2\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"         <span class=\"medCalcFontOneBold\">",
"          Percentile &gt;=5 and &lt;85:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Healthy weight",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_3\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"         <span class=\"medCalcFontOneBold\">",
"          Percentile &gt;=85 and &lt;95:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          At risk of overweight",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_4\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"         <span class=\"medCalcFontOneBold\">",
"          Percentile &gt;=95:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Overweight",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       These weight-for-stature standards are available as an alternative to BMI for assessment of over or undernutrition",
"in children ages two to five years. However, health care providers should consider using the BMI-for-age charts to be",
"consistent with current recommendations.",
"      </li>",
"      <li>",
"       This calculator uses measured standing height for children ages two to five years, and is not",
"valid for recumbent length.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Percentile conversion from Z Score is done by table look-up in the standard Normal Table. Percentiles are provided for Z Scores between -3.09 and 3.09.  Values beyond these extremes return percentiles of 0.1 and 99.9 respectively.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        LMS Parameters for Girls: Weight for Height     . National health and nutrition survey (NHANES), CDC/National Center for Health Statistics.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_37_2644=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"function alertNaN(){",
"alert('This field is improperly formatted. You may only input the digits 0-9 and a decimal point.');  ",
"doCalc = false; ",
"clrResults();",
"}",
"",
"",
"function validNumberField(event) {",
"var field = event.target;",
"",
"if(field && field != 'undefined' && field.attributes.type.nodeValue && (field.attributes.type.nodeValue == 'number')) {",
"var val = field.value;",
"var charCode = event.charCode;",
"var key = String.fromCharCode(charCode);",
"",
"if(charCode == 0) {",
"return true;",
"}",
"",
"if(key == ' ') {",
"alert('Numeric field cannot contain spaces.');",
"return false;",
"}	",
"		",
"if(val.length == 0) {",
"if(key == '+') { return true; }",
"if(key == '-') { return true; }	",
"if(key == '.') { return true; }",
"}",
"		",
"if(key == '.') { return validFloat(val, key); }",
"",
"if(isNaN(parseInt(key))) {",
"alertNaN();",
"return false;",
"}",
"	",
"return validFloat(val, key);",
"}",
"return true;",
"}",
"",
"",
"function validFloat(val, key) {",
"var currentVal = parseFloat(val + key);",
"if(isNaN(val + key) || isNaN(currentVal)) {",
"alertNaN();",
"}",
"return true;",
"}",
"",
"var currenttimeout;",
"",
"n = new Array;",
"var L = 0;",
"var M = 0;",
"var S = 0;",
"",
"n[0] = 50;",
"n[1] = 50.399;",
"n[2] = 50.798;",
"n[3] = 51.197;",
"n[4] = 51.595;",
"n[5] = 51.994;",
"n[6] = 52.392;",
"n[7] = 52.79;",
"n[8] = 53.188;",
"n[9] = 53.586;",
"n[10] = 53.983;",
"n[11] = 54.38;",
"n[12] = 54.776;",
"n[13] = 55.172;",
"n[14] = 55.567;",
"n[15] = 55.962;",
"n[16] = 56.356;",
"n[17] = 56.749;",
"n[18] = 57.142;",
"n[19] = 57.535;",
"n[20] = 57.926;",
"n[21] = 58.317;",
"n[22] = 58.706;",
"n[23] = 59.095;",
"n[24] = 59.483;",
"n[25] = 59.871;",
"n[26] = 60.257;",
"n[27] = 60.642;",
"n[28] = 61.026;",
"n[29] = 61.409;",
"n[30] = 61.791;",
"n[31] = 62.172;",
"n[32] = 62.552;",
"n[33] = 62.93;",
"n[34] = 63.307;",
"n[35] = 63.683;",
"n[36] = 64.058;",
"n[37] = 64.431;",
"n[38] = 64.803;",
"n[39] = 65.173;",
"n[40] = 65.542;",
"n[41] = 65.91;",
"n[42] = 66.276;",
"n[43] = 66.64;",
"n[44] = 67.003;",
"n[45] = 67.364;",
"n[46] = 67.724;",
"n[47] = 68.082;",
"n[48] = 68.439;",
"n[49] = 68.793;",
"n[50] = 69.146;",
"n[51] = 69.497;",
"n[52] = 69.847;",
"n[53] = 70.194;",
"n[54] = 70.54;",
"n[55] = 70.884;",
"n[56] = 71.226;",
"n[57] = 71.566;",
"n[58] = 71.904;",
"n[59] = 72.24;",
"n[60] = 72.575;",
"n[61] = 72.907;",
"n[62] = 73.237;",
"n[63] = 73.565;",
"n[64] = 73.891;",
"n[65] = 74.215;",
"n[66] = 74.537;",
"n[67] = 74.857;",
"n[68] = 75.175;",
"n[69] = 75.49;",
"n[70] = 75.804;",
"n[71] = 76.115;",
"n[72] = 76.424;",
"n[73] = 76.73;",
"n[74] = 77.035;",
"n[75] = 77.337;",
"n[76] = 77.637;",
"n[77] = 77.935;",
"n[78] = 78.23;",
"n[79] = 78.524;",
"n[80] = 78.814;",
"n[81] = 79.103;",
"n[82] = 79.389;",
"n[83] = 79.673;",
"n[84] = 79.955;",
"n[85] = 80.234;",
"n[86] = 80.511;",
"n[87] = 80.785;",
"n[88] = 81.057;",
"n[89] = 81.327;",
"n[90] = 81.594;",
"n[91] = 81.859;",
"n[92] = 82.121;",
"n[93] = 82.381;",
"n[94] = 82.639;",
"n[95] = 82.894;",
"n[96] = 83.147;",
"n[97] = 83.398;",
"n[98] = 83.646;",
"n[99] = 83.891;",
"n[100] = 84.134;",
"n[101] = 84.375;",
"n[102] = 84.614;",
"n[103] = 84.849;",
"n[104] = 85.083;",
"n[105] = 85.314;",
"n[106] = 85.543;",
"n[107] = 85.769;",
"n[108] = 85.993;",
"n[109] = 86.214;",
"n[110] = 86.433;",
"n[111] = 86.65;",
"n[112] = 86.864;",
"n[113] = 87.076;",
"n[114] = 87.286;",
"n[115] = 87.493;",
"n[116] = 87.698;",
"n[117] = 87.9;",
"n[118] = 88.1;",
"n[119] = 88.298;",
"n[120] = 88.493;",
"n[121] = 88.686;",
"n[122] = 88.877;",
"n[123] = 89.065;",
"n[124] = 89.251;",
"n[125] = 89.435;",
"n[126] = 89.617;",
"n[127] = 89.796;",
"n[128] = 89.973;",
"n[129] = 90.147;",
"n[130] = 90.32;",
"n[131] = 90.49;",
"n[132] = 90.658;",
"n[133] = 90.824;",
"n[134] = 90.988;",
"n[135] = 91.149;",
"n[136] = 91.308;",
"n[137] = 91.466;",
"n[138] = 91.621;",
"n[139] = 91.774;",
"n[140] = 91.924;",
"n[141] = 92.073;",
"n[142] = 92.22;",
"n[143] = 92.364;",
"n[144] = 92.507;",
"n[145] = 92.647;",
"n[146] = 92.785;",
"n[147] = 92.922;",
"n[148] = 93.056;",
"n[149] = 93.189;",
"n[150] = 93.319;",
"n[151] = 93.448;",
"n[152] = 93.574;",
"n[153] = 93.699;",
"n[154] = 93.822;",
"n[155] = 93.943;",
"n[156] = 94.062;",
"n[157] = 94.179;",
"n[158] = 94.295;",
"n[159] = 94.408;",
"n[160] = 94.52;",
"n[161] = 94.63;",
"n[162] = 94.738;",
"n[163] = 94.845;",
"n[164] = 94.95;",
"n[165] = 95.053;",
"n[166] = 95.154;",
"n[167] = 95.254;",
"n[168] = 95.352;",
"n[169] = 95.449;",
"n[170] = 95.543;",
"n[171] = 95.637;",
"n[172] = 95.728;",
"n[173] = 95.818;",
"n[174] = 95.907;",
"n[175] = 95.994;",
"n[176] = 96.08;",
"n[177] = 96.164;",
"n[178] = 96.246;",
"n[179] = 96.327;",
"n[180] = 96.407;",
"n[181] = 96.485;",
"n[182] = 96.562;",
"n[183] = 96.638;",
"n[184] = 96.712;",
"n[185] = 96.784;",
"n[186] = 96.856;",
"n[187] = 96.926;",
"n[188] = 96.995;",
"n[189] = 97.062;",
"n[190] = 97.128;",
"n[191] = 97.193;",
"n[192] = 97.257;",
"n[193] = 97.32;",
"n[194] = 97.381;",
"n[195] = 97.441;",
"n[196] = 97.5;",
"n[197] = 97.558;",
"n[198] = 97.615;",
"n[199] = 97.67;",
"n[200] = 97.725;",
"n[201] = 97.778;",
"n[202] = 97.831;",
"n[203] = 97.882;",
"n[204] = 97.932;",
"n[205] = 97.982;",
"n[206] = 98.03;",
"n[207] = 98.077;",
"n[208] = 98.124;",
"n[209] = 98.169;",
"n[210] = 98.214;",
"n[211] = 98.257;",
"n[212] = 98.3;",
"n[213] = 98.341;",
"n[214] = 98.382;",
"n[215] = 98.422;",
"n[216] = 98.461;",
"n[217] = 98.5;",
"n[218] = 98.537;",
"n[219] = 98.574;",
"n[220] = 98.61;",
"n[221] = 98.645;",
"n[222] = 98.679;",
"n[223] = 98.713;",
"n[224] = 98.745;",
"n[225] = 98.778;",
"n[226] = 98.809;",
"n[227] = 98.84;",
"n[228] = 98.87;",
"n[229] = 98.899;",
"n[230] = 98.928;",
"n[231] = 98.956;",
"n[232] = 98.983;",
"n[233] = 99.01;",
"n[234] = 99.036;",
"n[235] = 99.061;",
"n[236] = 99.086;",
"n[237] = 99.111;",
"n[238] = 99.134;",
"n[239] = 99.158;",
"n[240] = 99.18;",
"n[241] = 99.202;",
"n[242] = 99.224;",
"n[243] = 99.245;",
"n[244] = 99.266;",
"n[245] = 99.286;",
"n[246] = 99.305;",
"n[247] = 99.324;",
"n[248] = 99.343;",
"n[249] = 99.361;",
"n[250] = 99.379;",
"n[251] = 99.396;",
"n[252] = 99.413;",
"n[253] = 99.43;",
"n[254] = 99.446;",
"n[255] = 99.461;",
"n[256] = 99.477;",
"n[257] = 99.492;",
"n[258] = 99.506;",
"n[259] = 99.52;",
"n[260] = 99.534;",
"n[261] = 99.547;",
"n[262] = 99.56;",
"n[263] = 99.573;",
"n[264] = 99.585;",
"n[265] = 99.598;",
"n[266] = 99.609;",
"n[267] = 99.621;",
"n[268] = 99.632;",
"n[269] = 99.643;",
"n[270] = 99.653;",
"n[271] = 99.664;",
"n[272] = 99.674;",
"n[273] = 99.683;",
"n[274] = 99.693;",
"n[275] = 99.702;",
"n[276] = 99.711;",
"n[277] = 99.72;",
"n[278] = 99.728;",
"n[279] = 99.736;",
"n[280] = 99.744;",
"n[281] = 99.752;",
"n[282] = 99.76;",
"n[283] = 99.767;",
"n[284] = 99.774;",
"n[285] = 99.781;",
"n[286] = 99.788;",
"n[287] = 99.795;",
"n[288] = 99.801;",
"n[289] = 99.807;",
"n[290] = 99.813;",
"n[291] = 99.819;",
"n[292] = 99.825;",
"n[293] = 99.831;",
"n[294] = 99.836;",
"n[295] = 99.841;",
"n[296] = 99.846;",
"n[297] = 99.851;",
"n[298] = 99.856;",
"n[299] = 99.861;",
"n[300] = 99.865;",
"n[301] = 99.869;",
"n[302] = 99.874;",
"n[303] = 99.878;",
"n[304] = 99.882;",
"n[305] = 99.886;",
"n[306] = 99.889;",
"n[307] = 99.893;",
"n[308] = 99.896;",
"n[309] = 99.9;",
"",
"function ZtoPercentile(z){",
"with (document.CDCWeightForHeightGirls_form){",
"az = Math.abs(z);",
"if (z < -3.09) return 0.1;",
"if (z > 3.09) return 99.9;",
"thispercentile = n[Math.round(az * 100)];",
"if (z >= 0) { return thispercentile }",
"else { return 100 - thispercentile }",
"}}",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function CDCWeightForHeightGirls_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 2000);",
"",
"with(document.CDCWeightForHeightGirls_form){",
"",
"",
"doCalc = true;",
"param_value = parseFloat(Height_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Height_unit.options[Height_unit.selectedIndex].value.split('|');",
"Height = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"param_value = parseFloat(Weight_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Weight_unit.options[Weight_unit.selectedIndex].value.split('|');",
"Weight = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if(Height >= 77 && Height < 78){L = -0.935908436; M = 10.19868351; S = 0.081394448;};",
"if(Height >= 78 && Height < 79){L = -0.89621042; M = 10.42217324; S = 0.080780644;};",
"if(Height >= 79 && Height < 80){L = -0.863423474; M = 10.64473659; S = 0.080208403;};",
"if(Height >= 80 && Height < 81){L = -0.839250279; M = 10.86657146; S = 0.079687207;};",
"if(Height >= 81 && Height < 82){L = -0.825395013; M = 11.08788714; S = 0.079225952;};",
"if(Height >= 82 && Height < 83){L = -0.823487667; M = 11.30890397; S = 0.078832728;};",
"if(Height >= 83 && Height < 84){L = -0.834997067; M = 11.52985331; S = 0.078514592;};",
"if(Height >= 84 && Height < 85){L = -0.861125495; M = 11.75097872; S = 0.078277372;};",
"if(Height >= 85 && Height < 86){L = -0.90275588; M = 11.97253416; S = 0.078125431;};",
"if(Height >= 86 && Height < 87){L = -0.960308955; M = 12.19478883; S = 0.078061602;};",
"if(Height >= 87 && Height < 88){L = -1.033704489; M = 12.41802682; S = 0.078087089;};",
"if(Height >= 88 && Height < 89){L = -1.122303405; M = 12.64254963; S = 0.078201515;};",
"if(Height >= 89 && Height < 90){L = -1.224887418; M = 12.86867851; S = 0.07840306;};",
"if(Height >= 90 && Height < 91){L = -1.339655646; M = 13.09675786; S = 0.078688751;};",
"if(Height >= 91 && Height < 92){L = -1.464342037; M = 13.32715202; S = 0.079054697;};",
"if(Height >= 92 && Height < 93){L = -1.596224732; M = 13.56025156; S = 0.079496621;};",
"if(Height >= 93 && Height < 94){L = -1.732305592; M = 13.79646793; S = 0.080010179;};",
"if(Height >= 94 && Height < 95){L = -1.869440665; M = 14.03623165; S = 0.080591346;};",
"if(Height >= 95 && Height < 96){L = -2.004558693; M = 14.27998232; S = 0.081236502;};",
"if(Height >= 96 && Height < 97){L = -2.134764169; M = 14.5281658; S = 0.08194262;};",
"if(Height >= 97 && Height < 98){L = -2.257524917; M = 14.78122196; S = 0.082707038;};",
"if(Height >= 98 && Height < 99){L = -2.370762249; M = 15.03957746; S = 0.083527227;};",
"if(Height >= 99 && Height < 100){L = -2.472965302; M = 15.30363303; S = 0.084400264;};",
"if(Height >= 100 && Height < 101){L = -2.563140425; M = 15.5737634; S = 0.085322654;};",
"if(Height >= 101 && Height < 102){L = -2.640873937; M = 15.8503043; S = 0.086289668;};",
"if(Height >= 102 && Height < 103){L = -2.706178899; M = 16.1335593; S = 0.087295416;};",
"if(Height >= 103 && Height < 104){L = -2.759500412; M = 16.42379037; S = 0.088332358;};",
"if(Height >= 104 && Height < 105){L = -2.801578893; M = 16.72122308; S = 0.089391426;};",
"if(Height >= 105 && Height < 106){L = -2.833376069; M = 17.02604617; S = 0.090461996;};",
"if(Height >= 106 && Height < 107){L = -2.855987198; M = 17.33841369; S = 0.09153201;};",
"if(Height >= 107 && Height < 108){L = -2.870584724; M = 17.65844486; S = 0.092588053;};",
"if(Height >= 108 && Height < 109){L = -2.878341197; M = 17.98622785; S = 0.093615622;};",
"if(Height >= 109 && Height < 110){L = -2.880404823; M = 18.32181829; S = 0.094599184;};",
"if(Height >= 110 && Height < 111){L = -2.877853767; M = 18.66524194; S = 0.095522442;};",
"if(Height >= 111 && Height < 112){L = -2.871676584; M = 19.01649457; S = 0.096368448;};",
"if(Height >= 112 && Height < 113){L = -2.86277466; M = 19.37553957; S = 0.097119646;};",
"if(Height >= 113 && Height < 114){L = -2.851915004; M = 19.74231348; S = 0.097758211;};",
"if(Height >= 114 && Height < 115){L = -2.839760032; M = 20.11672014; S = 0.098265916;};",
"if(Height >= 115 && Height < 116){L = -2.826824189; M = 20.4986363; S = 0.098624434;};",
"if(Height >= 116 && Height < 117){L = -2.813480089; M = 20.88790914; S = 0.09881529;};",
"if(Height >= 117 && Height < 118){L = -2.799924586; M = 21.28435965; S = 0.09882;};",
"if(Height >= 118 && Height < 119){L = -2.786142221; M = 21.6877854; S = 0.098620143;};",
"if(Height >= 119 && Height < 120){L = -2.771843402; M = 22.09796571; S = 0.098197431;};",
"if(Height >= 120 && Height < 121){L = -2.756365595; M = 22.51466977; S = 0.097533789;};",
"if(Height >= 121 && Height < 122){L = -2.738514883; M = 22.93766971; S = 0.09661143;};",
"dp = decpts.options[decpts.selectedIndex].text;",
"Z_Score =  (power((Weight / M), L) - 1) / (L * S);",
"",
"if (doCalc) Z_Score_param.value = fixDP(Z_Score, dp);",
"",
"",
"",
"Percentile =  ZtoPercentile(Z_Score);",
"",
"if (doCalc) Percentile_param.value = fixDP(Percentile, dp);",
"",
"",
"",
"",
"if (doCalc){",
"rrclr();",
"if (Percentile <5){ document.getElementById('rr1_1').bgColor = '#cccccc';",
"}",
"if ((Percentile >=5) && (Percentile <85)){ document.getElementById('rr1_2').bgColor = '#cccccc';",
"}",
"if ((Percentile >=85) && (Percentile <95)){ document.getElementById('rr1_3').bgColor = '#cccccc';",
"}",
"if (Percentile >=95){ document.getElementById('rr1_4').bgColor = '#cccccc';",
"}",
"",
"}",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.CDCWeightForHeightGirls_form){",
"",
"if (Height_param.value && isNaN(Height_param.value)){ Height_param.value = ''; alertNaN(); }",
"if (Height_param.value && Height < 77) {",
"Height = 0;",
"Height_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Height is 77 cm.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Height_param.value && Height > 121.99) {",
"Height_param.value = \"\";",
"clrResults();",
"Height = 0;",
"doCalc = false;",
"alert(\"The maximum value for Height is 121.99 cm.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Weight_param.value && isNaN(Weight_param.value)){ Weight_param.value = ''; alertNaN(); }",
"if (Weight_param.value && Weight < 5) {",
"Weight = 0;",
"Weight_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Weight is 5 kg.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Weight_param.value && Weight > 200) {",
"Weight_param.value = \"\";",
"clrResults();",
"Weight = 0;",
"doCalc = false;",
"alert(\"The maximum value for Weight is 200 kg.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.CDCWeightForHeightGirls_form){",
"",
"Z_Score_param.value = '';",
"Percentile_param.value = '';",
"",
"rrclr();",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"document.getElementById('rr1_4').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f2_37_2644=null;
var title_f2_37_2645="Fasting and postprandial gastrointestinal motility";
var content_f2_37_2645=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fasting and postprandial gastrointestinal motility",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gastroduodenal manometry shows the normal interdigestive motor complex (left panel), in contrast to the irregular persistent phasic pressure activity seen posprandially (right panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from Malagelada JR, Camilleri M, Stanghellini M (Eds), Manometric Diagnosis of Gastrointestinal Motility Disorders, Thieme Inc, New York 1986.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_37_2645=[""].join("\n");
var outline_f2_37_2645=null;
var title_f2_37_2646="Schmorl nodes of the spine";
var content_f2_37_2646=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64470&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schmorl nodes of the spine: Findings on radiographic imaging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 514px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain lateral functional x-rays in flexion (A) and extension (B), showing hypermobility and spondylolisthesis at the Th11/12 level. Especially in flexion, severe kyphosis and spondylolisthesis were accompanied by sinking of the upper vertebra. Sagittal computed tomography scan (C) shows marginal bone sclerosis. Magnetic resonance imaging (D) shows the mass intensity is likely vertebral disc.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fukuta S, Miyamoto K, Atsushi I, et al. Unusual back pain caused by intervertebral disc degeneration associated with schmorl node at Th11/12 in a young athlete, successfully treated by anterior interbody fusion: a case report. Spine 2009; 34:E195. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_37_2646=[""].join("\n");
var outline_f2_37_2646=null;
var title_f2_37_2647="Treatment and prognosis of myocarditis in children";
var content_f2_37_2647=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of myocarditis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/37/2647/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/37/2647/contributors\">",
"     Catherine K Allan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/37/2647/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/37/2647/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/37/2647/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/37/2647/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/37/2647/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/37/2647/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/37/2647/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocarditis is a condition resulting from inflammation of the heart muscle. Myocellular damage results in myocardial dysfunction leading to heart failure. The clinical presentation can be acute or chronic; however, in contrast to adults, the majority of children with myocarditis present with acute or fulminant disease. Children with myocarditis are at risk for arrhythmias and hemodynamic compromise, resulting in significant morbidity and mortality.",
"   </p>",
"   <p>",
"    The treatment and prognosis of myocarditis in children are reviewed here. The causes, incidence, clinical manifestations and diagnosis of myocarditis in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=see_link\">",
"     \"Etiology and pathogenesis of myocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=see_link\">",
"     \"Clinical manifestations and diagnosis of myocarditis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstays of therapy for acute or fulminant myocarditis are monitoring, supportive care, and standard regimens for heart failure. Because of the high risk of arrhythmias and hemodynamic compromise, affected patients should be monitored in a pediatric intensive care unit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the acute phase, diuretics, afterload reducing agents, and inotropic drugs are used to treat heart failure. Intravenous agents, such as dopamine,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/48/25348?source=see_link\">",
"     dobutamine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/60/25542?source=see_link\">",
"     milrinone",
"    </a>",
"    , are used to prevent circulatory collapse in the case of acute fulminant myocarditis. Sedation, intubation, and mechanical ventilation are used to decrease metabolic demand in patients with cardiogenic shock. Mechanical ventilation also provides left ventricular afterload reduction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5386?source=see_link&amp;anchor=H5421324#H5421324\">",
"     \"Management of heart failure in infants and children\", section on 'Components of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants and children with severe circulatory compromise despite conventional medical intervention may benefit from mechanical support of the circulation using extracorporeal membrane oxygenation (ECMO) or a ventricular assist device (VAD). Temporary circulatory support may allow myocardial recovery or serve as a bridge to transplantation as demonstrated by the following [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A review of the multicenter Extracorporeal Life Support Organization (ELSO) registry data demonstrated 61 percent survival to hospital discharge for the 255 patients with myocarditis who were supported with ECMO [",
"      <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/5\">",
"       5",
"      </a>",
"      ]. Seven patients underwent orthotopic heart transplant and six survived to hospital discharge. Of the 100 patients who did not survive, ECMO support was withdrawn in 70 cases including 58 patients who had multiple organ failure.",
"     </li>",
"     <li>",
"      In another review of 514 patients admitted with acute myocarditis from the Pediatric Health Information System (PHIS) database, 17 of the 104 patients (16 percent) who were supported with ECMO or VAD underwent cardiac transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/7\">",
"       7",
"      </a>",
"      ]. In this group of patients that required temporary circulatory support, 25 died (24 percent) and the remaining patients showed recovery of myocardial function and survived to discharge after separation from VAD or ECMO support.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who progress from acute myocarditis to chronic heart failure, diuretics, angiotensin inhibitors,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"     digoxin",
"    </a>",
"    , and aldosterone inhibitors (ie,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/0/17414?source=see_link\">",
"     spironolactone",
"    </a>",
"    ) are well-accepted therapies, although there are no conclusive studies that prove benefit of these agents in pediatrics.",
"   </p>",
"   <p>",
"    Although beta blockers, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/63/40952?source=see_link\">",
"     carvedilol",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/11/15544?source=see_link\">",
"     metoprolol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    , are effective in improving systolic function in adults with heart failure, it is unclear whether they are beneficial in children. Data are limited, and the single randomized double-blinded trial of beta blockers in children and adolescents with heart failure reported carvedilol compared to placebo did not improve clinical heart failure outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/8\">",
"     8",
"    </a>",
"    ]. As the authors discuss, the results may reflect a difference in the effect of carvedilol on ventricular morphology in children compared to adults with heart failure, an underpowered study with too few patients to detect a beneficial effect because of the higher than expected improvement rate in the placebo-treated group, or an inability to detect benefit for children with specific cardiac diseases because of the heterogeneity of the enrolled patient population, which included patients with both dilated cardiomyopathy and congenital heart disease. Further treatment trials are needed to conclusively determine whether or not there is a role for beta blockers in the management of pediatric patients with heart failure due to myocarditis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Antiarrhythmic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of sinus rhythm may lead to acute deterioration or may exacerbate the symptoms of heart failure. However, most antiarrhythmic drugs have negative inotropic activity and may, therefore, worsen cardiac function and lead to acute hemodynamic instability. Thus, antiarrhythmic drugs should be used only when the expected benefit exceeds the risk, and only in consultation with a pediatric cardiologist. We recommend the following regimen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supraventricular or ventricular arrhythmias associated with acute hemodynamic instability should be converted electrically without delay.",
"     </li>",
"     <li>",
"      Supraventricular arrhythmias, particularly when associated with a rapid ventricular response, also may induce or aggravate heart failure. These arrhythmias should be converted promptly, either with drugs or with electrical cardioversion if medical therapy is unsuccessful. Because the mechanisms of atrial arrhythmias in acute myocarditis are diverse, a single treatment strategy will not work for all patients and individualized therapy is essential. As an example, automatic atrial arrhythmias, such as ectopic atrial tachycardia, may occur and do not respond to electrical cardioversion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=see_link\">",
"       \"Management of supraventricular tachycardia in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      High-grade ventricular ectopy should be treated cautiously with antiarrhythmic drugs.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"       Lidocaine",
"      </a>",
"      infusion is our first-line treatment, given the relative safety of this drug compared to other antiarrhythmic agents. Although",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"       amiodarone",
"      </a>",
"      is widely used to treat ventricular ectopy in adults, the safety profile in children is less well demonstrated [",
"      <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/9\">",
"       9",
"      </a>",
"      ]. Amiodarone may be proarrhythmic and rapid infusion may precipitate severe hypotension. Thus, this agent should be used only in collaboration with an experienced pediatric cardiologist.",
"     </li>",
"     <li>",
"      Complete heart block is an indication for transvenous pacing. This conduction abnormality is often transient; as a result, use of a temporary pacemaker should be the first step.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Providing complete mechanical support of the circulation with ECMO or a ventricular assist device (VAD) can be lifesaving in children with acute fulminant myocarditis and hemodynamically significant arrhythmias. Since many patients with fulminant disease recover completely if they can be supported through their acute illness, we use ECMO or VAD in the setting of a significant and persistent arrhythmia to allow myocardial recovery and safe pharmacologic therapy for the rhythm disturbance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial damage in infectious myocarditis is thought to be due to both direct viral damage and the immune response to infection. This dual mechanism is the basis for proposing immunosuppressive or immunomodulatory therapies. However, this approach has not been successful in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=see_link\">",
"     \"Etiology and pathogenesis of myocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This was illustrated by the Myocarditis Treatment Trial, in which 111 patients with a histopathologic diagnosis of myocarditis and a left ventricular ejection fraction (LVEF) of less than 45 percent were randomly assigned to receive conventional therapy alone or immunosuppression with either",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/10/2216?source=see_link\">",
"     azathioprine",
"    </a>",
"    for 28 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/10\">",
"     10",
"    </a>",
"    ]. There was no difference in outcome in the two treatment groups. In all patients, the LVEF improved from 25 to 34 percent and the mortality rate was 20 percent at one year and 56 percent at 4.3 years. A more robust inflammatory response was associated with less severe disease and a greater improvement in cardiac function.",
"   </p>",
"   <p>",
"    However, this study had a number of limitations, and the results may not be applicable to children or patients who present with cardiogenic shock or primary arrhythmias.",
"   </p>",
"   <p>",
"    The limitations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subjects could be enrolled for up to two years after symptom onset. Since relatively few participants had fulminant myocarditis, the optimal timing for immunosuppressive treatment may have passed.",
"     </li>",
"     <li>",
"      The use of Dallas criteria for the diagnosis of myocarditis may not have identified the patients who would benefit from immunosuppression. Markers of immune activation rather than cellular infiltrates (Dallas criteria) may identify such patients.",
"     </li>",
"     <li>",
"      Only a small number of patients with biopsy-proven myocarditis (both with and without myocyte necrosis by Dallas criteria) were enrolled at five years. Thus, little information is available on long-term outcome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data regarding the efficacy of immunosuppressive therapy for myocarditis in children are limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case series and a small trial are inconclusive with respect to the beneficial effects of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other immunosuppressive agents (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/10/2216?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ) on left ventricular function and ventricular arrhythmias in children with myocarditis, but definitive data are lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. This is illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a single center trial, 43 children with biopsy proven myocarditis were randomly assigned to receive conventional treatment alone or conventional treatment combined with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      , prednisone and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/10/2216?source=see_link\">",
"       azathioprine",
"      </a>",
"      , or prednisone and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/14\">",
"       14",
"      </a>",
"      ]. Left ventricular end diastolic dimension, pulmonary capillary wedge pressure, heart rate, and biopsy-proven inflammation decreased and ejection fraction, cardiac index, and stroke volume increased in children who received prednisone and either cyclosporine or azathioprine but not those treated with prednisone alone or conventional medical therapy. However, interpretation of these results is limited by the small sample size, an incomplete description of the duration and severity of illness, and biopsy findings of mild or moderate rather than severe inflammation in the majority of patients.",
"     </li>",
"     <li>",
"      In a retrospective review of 41 patients with either biopsy-proven myocarditis or new myocardial dysfunction plus laboratory proof of concomitant viral infection, there was no difference in survival or need for transplantation at one and five years follow-up for patients treated with conventional medical therapy versus those treated with conventional therapy plus steroids or without intravenous gamma globulin (IVIG) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ECG changes, heart size, and systolic function improved in seven survivors among eight children with biopsy-proven myocarditis treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      (one also received",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/10/2216?source=see_link\">",
"       azathioprine",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among eight children with myocarditis and ventricular ectopic rhythm, corticosteroid treatment was associated with resolution of the arrhythmia in four patients, improvement in two, and no change in two [",
"      <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recurrence of symptoms and LV dysfunction in some patients when immunosuppression was discontinued supports its beneficial role [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/12\">",
"     12",
"    </a>",
"    ]. However, these results must be interpreted with caution because improvement may be related to the natural history of the disease independent of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     IVIG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of intravenous gamma globulin (IVIG) to treat myocarditis was suggested by its efficacy in other immune-mediated diseases. Its use is also supported by experimental data in which polyclonal immunoglobulin protects against myocardial or arterial damage in mouse models of viral and autoimmune myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although no randomized controlled trials of IVIG for the treatment of myocarditis in children have been reported, some clinical evidence suggests it may be beneficial. In a retrospective review from two pediatric hospitals, 21 children with presumed acute myocarditis treated with high dose IVIG (2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    over 24 hours) were compared to 25 historical controls treated with conventional supportive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients treated with IVIG demonstrated greater ventricular fractional shortening by echocardiography at 3 to 6 months and 6 to 12 months after treatment compared to controls, and smaller left ventricular end diastolic dimension at 3 to 6 months. There was a trend toward improved survival after one year in patients who received IVIG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use high dose IVIG (2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    over 24 hours) for children with acute myocarditis demonstrated by endomyocardial biopsy. We reserve the use of corticosteroids or other immunosuppressive agents for myocarditis associated with systemic autoimmune diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192187353\">",
"    <span class=\"h2\">",
"     Survival and heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the overall survival rate for children with myocarditis is 90 percent; however, most survivors require intensive care and interventions for heart failure.",
"   </p>",
"   <p>",
"    This was illustrated in a large case series of 514 patients from the Pediatric Health Information System (PHIS) database with the following findings [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mortality of 7 percent (37 deaths).",
"     </li>",
"     <li>",
"      Intensive care unit admission for 413 patients (80 percent) who received the following interventions for cardiorespiratory failure:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Mechanical ventilation for 228 patients (44 percent)",
"     </li>",
"     <li>",
"      Extracorporeal membrane oxygenation (ECMO) for 97 patients (19 percent)",
"     </li>",
"     <li>",
"      Ventricular assist device (VAD) for 22 patients (4 percent)",
"     </li>",
"     <li>",
"      Both VAD and ECMO for 15 patients (3 percent)",
"     </li>",
"     <li>",
"      Heart transplantation 21 patients (4 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multivariant analysis demonstrated that mortality was associated with the use of ECMO, VAD, and vasoactive medication (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/60/25542?source=see_link\">",
"       milrinone",
"      </a>",
"      , dopamine, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/48/25348?source=see_link\">",
"       dobutamine",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a retrospective review of 28 cases of clinically diagnosed myocarditis from a single institution, factors predictive of unremitting cardiac failure included ejection fraction &lt;30 percent, shortening fraction &lt;15 percent, left ventricular (LV) dilatation, and moderate to severe mitral regurgitation at the time of admission [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192187346\">",
"    <span class=\"h2\">",
"     Long-term follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little information is available on the natural history of myocarditis in children. Limitations of these reports include the small number of patients, the inclusion of other causes of myocardial dysfunction, the lack of biopsy confirmation of myocarditis, and the failure to distinguish between acute and fulminant myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/18,20-24\">",
"     18,20-24",
"    </a>",
"    ]. Although similar data are not available for children, complete recovery is more likely in adults with fulminant compared to acute myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review, 41 patients with acute myocarditis proven either by endomyocardial biopsy or by the presence of cardiac dysfunction and coincident proven viral infection were followed up to five years following diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/15\">",
"       15",
"      </a>",
"      ]. Sixty-six percent showed complete recovery, 10 percent partial recovery, and 24 percent died or required transplantation.",
"     </li>",
"     <li>",
"      In one report, 114 patients with myocarditis or dilated cardiomyopathy were followed for up to 13 years. Of these 114 patients, 35 had acute and 35 borderline myocarditis diagnosed by EMB and were treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      plus",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/21\">",
"       21",
"      </a>",
"      ]. The remaining 44 had noninflammatory cardiomyopathy by EMB and were treated with conventional anticongestive therapy alone. For the 70 patients with confirmed myocarditis, one year survival was 96 percent as compared to 61 percent for those with noninflammatory dilated cardiomyopathy. Thirteen year survival was 83 percent in the myocarditis group, although the number of patients with this duration of follow-up was quite small",
"      <span class=\"nowrap\">",
"       (6/114).",
"      </span>",
"      Among patients with acute myocarditis, 73 percent had complete or almost complete histologic resolution of myocarditis at the six-month EMB, 13 year transplant free survival was 97 percent, and 79 percent of survivors had normal LV function. Among patients with borderline myocarditis, 77 percent had complete or almost complete histologic resolution of myocarditis at the six-month EMB, 13-year transplant free survival was 70 percent and 64 percent of survivors had normal LV function. This study is limited by the absence of patients with clinical signs of fulminant myocarditis.",
"     </li>",
"     <li>",
"      In a series of 161 infants and children with primary myocardial disease (including myocarditis, nonobstructive cardiomyopathy, endocardial fibroelastosis, and unknown cause) seen over a 30-year period, approximately equal proportions of patients recovered completely, died, or had residual dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 36 children with histologically confirmed lymphocytic myocarditis, 34 were treated with corticosteroids, four required extracorporeal membrane oxygenation support, and three underwent heart transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/22\">",
"       22",
"      </a>",
"      ]. Median follow-up was 19 months. Transplant-free survival was 86 and 79 percent at one month and two years, respectively. The median period for recovery of LV ejection fraction &gt;55 percent was 2.8 months. None of the survivors reported cardiac symptoms or restrictions in physical activity, and none required antiarrhythmic treatment.",
"     </li>",
"     <li>",
"      Among 29 children with acute dilated cardiomyopathy, all nine with biopsy-proven myocarditis recovered fully one year after diagnosis compared to 4 of 18 with nonspecific pathology [",
"      <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/23\">",
"       23",
"      </a>",
"      ]. However, only patients with proven myocarditis received immunosuppressive therapy.",
"     </li>",
"     <li>",
"      Although patients with acute fulminant myocarditis may need substantial hemodynamic support, including inotropic agents, mechanical ventilation, and possibly ECMO, outcomes may be better for this group than for those with acute or chronic myocarditis as demonstrated by the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In one small series of 11 pediatric patients, survival to discharge was 91 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/26\">",
"       26",
"      </a>",
"      ]. The 10 survivors had full recovery of ventricular function and were asymptomatic at last follow-up.",
"     </li>",
"     <li>",
"      In a second case series of 20 patients (median age 12.7 years) admitted to a pediatric cardiac intensive care unit between 1996 and 2008, survival to discharge was 85 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/27\">",
"       27",
"      </a>",
"      ]. Seven of ten patients who received ECMO therapy survived. One survivor underwent cardiac transplantation. Nonsurvivors compared with survivors had higher peak serum levels of lactate, creatinine, and aspartate aminotransferase.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who do not fully recover cardiac function may develop dilated cardiomyopathy. This disorder is preceded by myocarditis in 27 to 40 percent of cases in children [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2647/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. However, the proportion of children with acute myocarditis who develop dilated cardiomyopathy is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myocarditis should be suspected in a child with the acute onset of heart failure and no structural heart disease, especially after a viral prodrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=see_link\">",
"       \"Clinical manifestations and diagnosis of myocarditis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Because of the high risk of arrhythmias and hemodynamic compromise, affected patients should be monitored in a pediatric intensive care unit.",
"     </li>",
"     <li>",
"      During the acute phase, heart failure should be treated with diuretics, inotropes, and afterload reducing agents. Patients with severe circulatory compromise despite conventional medical intervention may benefit from temporary mechanical support of the circulation using ECMO or a ventricular assist device. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Heart failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who develop chronic heart failure, treatment options include diuretics, angiotensin inhibitors,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"       digoxin",
"      </a>",
"      , and aldosterone inhibitors (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/0/17414?source=see_link\">",
"       spironolactone",
"      </a>",
"      ) and any combination of these drugs. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Heart failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiarrhythmic drugs should be used cautiously, as most have negative inotropic activity and may aggravate heart failure.",
"     </li>",
"     <li>",
"      Although there is no expert consensus and data are very limited regarding use of immunomodulatory treatments for patients with acute myocarditis, use of IVIG (2",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      over 24 hours) is a widely used and accepted practice. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Immunosuppressive therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/1\">",
"      Duncan BW, Bohn DJ, Atz AM, et al. Mechanical circulatory support for the treatment of children with acute fulminant myocarditis. J Thorac Cardiovasc Surg 2001; 122:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/2\">",
"      Grundl PD, Miller SA, del Nido PJ, et al. Successful treatment of acute myocarditis using extracorporeal membrane oxygenation. Crit Care Med 1993; 21:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/3\">",
"      del Nido PJ, Armitage JM, Fricker FJ, et al. Extracorporeal membrane oxygenation support as a bridge to pediatric heart transplantation. Circulation 1994; 90:II66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/4\">",
"      Hetzer R, Loebe M, Potapov EV, et al. Circulatory support with pneumatic paracorporeal ventricular assist device in infants and children. Ann Thorac Surg 1998; 66:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/5\">",
"      Rajagopal SK, Almond CS, Laussen PC, et al. Extracorporeal membrane oxygenation for the support of infants, children, and young adults with acute myocarditis: a review of the Extracorporeal Life Support Organization registry. Crit Care Med 2010; 38:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/6\">",
"      Morales DL, Almond CS, Jaquiss RD, et al. Bridging children of all sizes to cardiac transplantation: the initial multicenter North American experience with the Berlin Heart EXCOR ventricular assist device. J Heart Lung Transplant 2011; 30:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/7\">",
"      Ghelani SJ, Spaeder MC, Pastor W, et al. Demographics, trends, and outcomes in pediatric acute myocarditis in the United States, 2006 to 2011. Circ Cardiovasc Qual Outcomes 2012; 5:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/8\">",
"      Shaddy RE, Boucek MM, Hsu DT, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007; 298:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/9\">",
"      Saul JP, Scott WA, Brown S, et al. Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, double-blind, antiarrhythmic drug trial. Circulation 2005; 112:3470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/10\">",
"      Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995; 333:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/11\">",
"      Balaji S, Wiles HB, Sens MA, Gillette PC. Immunosuppressive treatment for myocarditis and borderline myocarditis in children with ventricular ectopic rhythm. Br Heart J 1994; 72:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/12\">",
"      Chan KY, Iwahara M, Benson LN, et al. Immunosuppressive therapy in the management of acute myocarditis in children: a clinical trial. J Am Coll Cardiol 1991; 17:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/13\">",
"      Schmaltz AA, Demel KP, Kallenberg R, et al. Immunosuppressive therapy of chronic myocarditis in children: three cases and the design of a randomized prospective trial of therapy. Pediatr Cardiol 1998; 19:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/14\">",
"      Camargo PR, Snitcowsky R, da Luz PL, et al. Favorable effects of immunosuppressive therapy in children with dilated cardiomyopathy and active myocarditis. Pediatr Cardiol 1995; 16:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/15\">",
"      English RF, Janosky JE, Ettedgui JA, Webber SA. Outcomes for children with acute myocarditis. Cardiol Young 2004; 14:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/16\">",
"      Weller AH, Hall M, Huber SA. Polyclonal immunoglobulin therapy protects against cardiac damage in experimental coxsackievirus-induced myocarditis. Eur Heart J 1992; 13:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/17\">",
"      George J, Barshack I, Malka E, et al. The effect of intravenous immunoglobulins on the progression of experimental autoimmune myocarditis in the rat. Exp Mol Pathol 2001; 71:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/18\">",
"      Drucker NA, Colan SD, Lewis AB, et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 1994; 89:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/19\">",
"      K&uuml;hn B, Shapiro ED, Walls TA, Friedman AH. Predictors of outcome of myocarditis. Pediatr Cardiol 2004; 25:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/20\">",
"      Greenwood RD, Nadas AS, Fyler DC. The clinical course of primary myocardial disease in infants and children. Am Heart J 1976; 92:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/21\">",
"      Gagliardi MG, Bevilacqua M, Bassano C, et al. Long term follow up of children with myocarditis treated by immunosuppression and of children with dilated cardiomyopathy. Heart 2004; 90:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/22\">",
"      Lee KJ, McCrindle BW, Bohn DJ, et al. Clinical outcomes of acute myocarditis in childhood. Heart 1999; 82:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/23\">",
"      Kleinert S, Weintraub RG, Wilkinson JL, Chow CW. Myocarditis in children with dilated cardiomyopathy: incidence and outcome after dual therapy immunosuppression. J Heart Lung Transplant 1997; 16:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/24\">",
"      Venugopalan P, Houston AB, Agarwal AK. The outcome of idiopathic dilated cardiomyopathy and myocarditis in children from the west of Scotland. Int J Cardiol 2001; 78:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/25\">",
"      McCarthy RE 3rd, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000; 342:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/26\">",
"      Amabile N, Fraisse A, Bouvenot J, et al. Outcome of acute fulminant myocarditis in children. Heart 2006; 92:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/27\">",
"      Teele SA, Allan CK, Laussen PC, et al. Management and outcomes in pediatric patients presenting with acute fulminant myocarditis. J Pediatr 2011; 158:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/28\">",
"      Lipshultz SE, Sleeper LA, Towbin JA, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 2003; 348:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2647/abstract/29\">",
"      Nugent AW, Daubeney PE, Chondros P, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med 2003; 348:1639.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5761 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-FBD0C7583D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_37_2647=[""].join("\n");
var outline_f2_37_2647=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - IVIG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H192187353\">",
"      Survival and heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H192187346\">",
"      Long-term follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=related_link\">",
"      Etiology and pathogenesis of myocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5386?source=related_link\">",
"      Management of heart failure in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=related_link\">",
"      Management of supraventricular tachycardia in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_37_2648="Nonarrhythmic complications of mitral valve prolapse";
var content_f2_37_2648=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonarrhythmic complications of mitral valve prolapse",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/37/2648/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/37/2648/contributors\">",
"     Sorin Pislaru, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/37/2648/contributors\">",
"     Maurice Enriquez-Sarano, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/37/2648/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/37/2648/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/37/2648/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/37/2648/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/37/2648/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral regurgitation is the most frequent valve disease in the US population [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/1\">",
"     1",
"    </a>",
"    ], with mitral valve prolapse (MVP) the most common cause of mitral regurgitation requiring surgical correction [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/2\">",
"     2",
"    </a>",
"    ]. While the diagnosis of MVP is relatively simple (the clinical finding of a systolic click",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    murmur leads to confirmatory echocardiography), the medical literature is somewhat confusing. This is related to the overlap between denomination of MVP clinical syndromes, etiology and mechanisms, and to a change in echocardiographic diagnostic criteria for MVP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13705?source=see_link\">",
"     \"Definition and diagnosis of mitral valve prolapse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Major nonarrhythmic complications of mitral valve prolapse including MR, heart failure (HF), infective endocarditis (IE), and cerebrovascular accidents will be reviewed here. Other conditions associated with MVP are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3476?source=see_link\">",
"     \"Mitral valve prolapse syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17719?source=see_link\">",
"     \"Arrhythmic complications of mitral valve prolapse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been estimated that the overall risk of serious complications in MVP is about",
"    <strong>",
"     1 percent per year",
"    </strong>",
"    in patients with clinically and echocardiographically diagnosed disease; this is a not a cumulative risk since some patients have multiple complications [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/3\">",
"     3",
"    </a>",
"    ]. However, patients with MVP can be divided into widely variable risk groups, with the high-risk group having a cardiovascular mortality of 3.4 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most important risk factors for mortality are presence of moderate to severe MR and left ventricular ejection fraction less than 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/4\">",
"     4",
"    </a>",
"    ]. The severity of MR also correlates with the requirement for valve replacement and the incidence of infective endocarditis, cerebral embolism, and death (",
"    <a class=\"graphic graphic_figure graphicRef57338 \" href=\"UTD.htm?33/17/34077\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6649?source=see_link&amp;anchor=H2#H2\">",
"     \"Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet\", section on 'Natural history of mitral valve prolapse'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MITRAL REGURGITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary mitral valve prolapse is the most common etiology of pure mitral regurgitation (MR), accounting for over 50 percent of cases; it also accounts for over 60 percent of patients with ruptured chordae tendineae [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MR in MVP is a consequence of myxomatous degeneration of the leaflets and chordae, leading to loss of mitral valve competence. The severity of leaflet dysfunction can progress as the abnormal leaflet tissue stretches, resulting in further prolapse and increasing regurgitation. The ventricular and atrial consequences of MR are initiated by volume overload with increased preload and left-ventricular and left-atrial enlargement. Impedance to ejection is reduced (due to regurgitation into the lower pressure left atrium), and therefore impaired systolic function may be masked by preservation of the left ventricular ejection fraction. Indeed, in patients with MVP and severe MR, borderline normal ejection fraction (50 to 60 percent) and increased end-systolic diameter imply overt left-ventricular dysfunction. The left ventricular dysfunction is unmasked at time of surgery, with a postoperative average immediate ejection fraction drop of about 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6649?source=see_link&amp;anchor=H2#H2\">",
"     \"Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet\", section on 'Natural history of mitral valve prolapse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of patients with MVP have only trace or mild MR [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/9\">",
"     9",
"    </a>",
"    ]; hemodynamically significant MR is uncommon, occurring in only 2 to 7 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. However, the relatively high prevalence of MVP accounts for the observation that more than 25 percent of mitral valve replacement surgeries are currently performed for severe MR secondary to myxomatous degeneration of the valve and subvalvular structures. Progression of MR may occur in patients with all degrees of MR at baseline but tends to be more intense in patients with pre-existent MR (as MR begets more MR). In patients with MR at baseline, the regurgitant volume increases by a mean of 7",
"    <span class=\"nowrap\">",
"     mL/beat",
"    </span>",
"    per year [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms of progression of MR are varied. In patients with chronic MR, with the progressive enlargement of cavities the LA compliance increases so that with the same regurgitant orifice the regurgitant volume increases as the V wave in the LA declines. Development of chronic progressive enlargement of the mitral annulus or new ruptured chords will tend to separate the mitral leaflets further during systole, leading to progressive increase in the regurgitant orifice.",
"   </p>",
"   <p>",
"    Acute severe MR (such as occurring after chordal rupture with large unsupported segments) is poorly tolerated and usually requires rapid surgical intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21904137\">",
"    <span class=\"h2\">",
"     Role of quantification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formal quantification of mitral regurgitation is endorsed by all major society guidelines (including the American College of Cardiology",
"    <span class=\"nowrap\">",
"     [ACC/AHA],",
"    </span>",
"    European Society of Cardiology [ESC], and American Society of Echocardiography [ASE]) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Our observations that quantitative measures of mitral regurgitation (regurgitant volume and orifice) are essential predictors of outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/16\">",
"     16",
"    </a>",
"    ] have been confirmed in two independent prospective studies totaling, with our own, more than 1000 patients followed long term [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Echocardiography is the key diagnostic modality; formal quantification requires comprehensive integration of color-flow imaging and pulsed and continuous wave Doppler-echocardiography.",
"   </p>",
"   <p>",
"    Quantitative assessment by continuity equation or proximal isovelocity surface area method (PISA) allows measurement of effective regurgitant orifice area (ERO) and regurgitant volume (RVol); severe mitral regurgitation is present with ERO&gt;40 mm",
"    <sup>",
"     2",
"    </sup>",
"    and RVol&gt;60 mL. Quantitation of regurgitation severity must also take into account the highly dynamic nature of ERO with MVP. Indeed, some patients have virtually no regurgitation in the initial part of systole, with a sudden increase in ERO (sometimes to very large values) during late systole [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/19\">",
"     19",
"    </a>",
"    ]. We have shown that patients with MVP and purely mid-late systolic MR have a more benign outcome than those with holosystolic MR. In mid-late systolic MR, regurgitant volume provides information more reflective of MR severity than ERO [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to increasing the likelihood of valve",
"    <span class=\"nowrap\">",
"     replacement/repair,",
"    </span>",
"    presence of moderate to severe MR with MVP has been implicated as a marker for complications such as IE, arrhythmias, and cardiovascular mortality, including sudden death [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Most of the increased risk of arrhythmias and sudden death is directly related to valvular insufficiency, although cases of sudden death have been reported in patients in whom minimal prolapse was the only abnormality found at autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17719?source=see_link&amp;anchor=H3#H3\">",
"     \"Arrhythmic complications of mitral valve prolapse\", section on 'Sudden cardiac death'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Natural history and role of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of MR in mitral valve prolapse and the indications for mitral valve surgery in such patients are discussed in detail separately (",
"    <a class=\"graphic graphic_table graphicRef51845 \" href=\"UTD.htm?34/19/35132\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6649?source=see_link\">",
"     \"Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25096?source=see_link\">",
"     \"Indications for corrective surgery in severe chronic primary mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PROLAPSE OF OTHER VALVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral valve prolapse may be accompanied by myxomatous degeneration and prolapse of other valves, particularly the tricuspid valve. Although data are limited, small studies suggest that there is concurrent tricuspid valve prolapse in approximately 40 percent and aortic and pulmonic valve prolapse in up to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/13,23,24\">",
"     13,23,24",
"    </a>",
"    ]. These lesions occur with or without valvular regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of concurrent tricuspid repair in patients undergoing mitral valve surgery for MVP with severe MR is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36697?source=see_link&amp;anchor=H22#H22\">",
"     \"Surgical procedures for severe chronic mitral regurgitation\", section on 'Concurrent tricuspid repair'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INFECTIVE ENDOCARDITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infective endocarditis occurs at an increased frequency in patients with MVP when compared to those with a normal mitral valve, although the absolute risk of infection is low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the last few decades, there has been a shift in the spectrum of underlying cardiac lesions in patients with IE, as MVP has replaced rheumatic heart disease as the most common disorder in developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. One study, for example, compared patients with IE in the 1970s to those diagnosed in the 1980s: The incidence of MVP rose from 6 percent in the earlier group to 22 percent in the later group [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/26\">",
"     26",
"    </a>",
"    ]. In a systematic review of all patients undergoing surgery for native valve endocarditis at Mayo Clinic between 1984 and 2005, MVP was present in 43 percent of patients with mitral valve endocarditis and was an independent risk factor for development of endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The exact risk of developing IE in patients with MVP is difficult to determine, but estimates can be made based on the presumed incidence of IE in the general population of 1 per 20,000 per year. An overview of available series indicates a fivefold relative risk for the development of IE in the presence of MVP, and a much higher risk if a systolic murmur of MR is also present [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The absolute risk of developing IE among patients with MVP has been estimated to be one in 5725 patients per year, assuming a 4 percent prevalence of MVP in the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Based upon similar assumptions, the annual risk of developing IE is one in 1920 in the presence of MR diagnosed by auscultation and one in 21,950 in the absence of a murmur [",
"      <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Male gender, older age, thickened and redundant mitral valve leaflets, and the presence of a MR murmur, especially in older patients, predispose individuals with MVP to the development of IE [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. A retrospective study of 319 subjects with thickened mitral valve leaflets revealed that 11 patients had developed IE versus none in patients with MVP who had normal valve thickness [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocarditis prophylaxis is no longer recommended by the current",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for patients with MVP [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although MVP is associated with an increased risk of endocarditis, there are no convincing data that antibiotic prophylaxis is effective in preventing episodes of endocarditis. IE can occur in spite of antibiotic prophylaxis, and many cases of failure of prophylaxis have been reported with bacteria sensitive to the antibiotic given preventively [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/33\">",
"     33",
"    </a>",
"    ]. Furthermore, transient everyday episodes of bacteremia account for a large proportion of cases of endocarditis. In one survey, only 44 percent had clear, predisposing events that might have been an indication for antibiotic prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/26\">",
"     26",
"    </a>",
"    ]. Studies in the Netherlands have also concluded that only a small number of cases of IE are prevented by antibiotic prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further supporting restricted use of antibiotic prophylaxis, the incidence of endocarditis caused by group viridans streptococci in Olmsted County has, if anything, decreased after the 2007 publication of the updated guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;We concur with the 2007 AHA and 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on infective endocarditis, which recommends endocarditis prophylaxis for patients only at the highest risk [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients with mitral valve prolapse, including those with mitral regurgitation, are",
"    <strong>",
"     not",
"    </strong>",
"    included in this highest risk group. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TRANSIENT ISCHEMIC ATTACKS AND CEREBRAL VASCULAR ACCIDENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Does a relationship exist between stroke and MVP?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical studies suggest a weak relationship between MVP and stroke. A study from the Mayo Clinic examined the clinical course of 777 patients with MVP (mean age 49 years) who were followed for a mean of 5.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/37\">",
"     37",
"    </a>",
"    ]. Ischemic neurologic events occurred in 30 patients (4 percent). This event rate was significantly increased compared to the expected rate of neurologic events in the community (relative risk 2.2, 95 percent CI 1.5 to 3.2). However, this high life-time risk of ischemic cerebral events was not uniformly distributed. The risk was non-detectable in MVP without leaflet thickening, mild for MVP with leaflet thickening under medical management, and high after either atrial fibrillation or cardiac surgery. The estimated 10-year risk of an embolic event (including events after mitral surgery) was significantly greater than the expected community event rates for patients over age 50, for those who developed atrial fibrillation, and for those with thickened mitral valve leaflets (adjusted relative risks 2.3, 5.9, and 3.5, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other reports using current echocardiographic criteria for MVP have found no relationship between MVP and cerebral events [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/9,38\">",
"     9,38",
"    </a>",
"    ]. In a case-control study comparing 213 patients 45 years old or younger with ischemic stroke or transient ischemic attacks with 263 control subjects, the prevalence of MVP was similar in the two groups (1.9 and 2.7 percent; odds ratio adjusted for age and sex was 0.59; 95% CI 0.12-2.50).",
"   </p>",
"   <p>",
"    These observations indicate that cerebrovascular events are rare in young patients with MVP and the attributable risk to MVP of strokes in young patients is very low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Potential mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between thromboembolic events and mitral valve prolapse most likely is related to the prevalence of other risk factors for embolism, primarily atrial fibrillation, which may be paroxysmal and asymptomatic. The current guidelines for therapy are based upon this view.",
"   </p>",
"   <p>",
"    Other mechanisms have been proposed but have not been confirmed in larger studies: The presence of fibrinous exudates on myxomatous mitral valve leaflets [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/39\">",
"     39",
"    </a>",
"    ] or at the angle formed by the prolapsing posterior mitral valve leaflet and the left atrial wall [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/40\">",
"     40",
"    </a>",
"    ]. Endothelial denudation of valve leaflet surfaces or chordal attachment sites may predispose to platelet deposition and embolization. Abnormal platelet function has been documented in some, but not all, studies of patients with MVP with MR [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Recommendations for antithrombotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the uncertainty about the association of MVP and cerebral vascular events, there is no consensus regarding prophylactic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy. The following recommendations are consistent with 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines (",
"    <a class=\"graphic graphic_table graphicRef77759 \" href=\"UTD.htm?29/15/29948\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antithrombotic therapy is not recommended in patients without a history of systemic embolism, unexplained transient ischemic attacks, ischemic stroke, or atrial fibrillation. However,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy (75 to 325 mg) may be considered for patients in sinus rhythm with echocardiographic evidence of high risk MVP.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      (75 to 325",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      is recommended in patients with unexplained transient ischemic attacks in sinus rhythm with no atrial thrombi.",
"     </li>",
"     <li>",
"      Anticoagulation is recommended in patients with documented systemic embolism or recurrent transient ischemic attacks despite",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Embolic events in adults with MVP and only mild MR are presumed due to paroxysmal AF and should be treated as in other cases of non-valvular AF. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with MVP and moderate to severe MR, documented AF or embolic events due to presumed paroxysmal AF should be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      anticoagulation (goal INR 2.5, range 2.0 to 3.0). The use of new oral anticoagulants (direct thrombin and Xa inhibitors) has not been studied in these patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar recommendations are included in the 2012 ESC guidelines for valvular heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2648/abstract/15\">",
"     15",
"    </a>",
"    ], although they note that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy is reasonable for patients with MVP and history of stroke who do not have MR, atrial fibrillation, left atrial thrombus, leaflet thickening (5mm or greater), or redundancy of the valve leaflets. General discussions of antithrombotic therapy for atrial fibrillation and stroke are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32281?source=see_link\">",
"     \"Secondary prevention for specific causes of ischemic stroke and transient ischemic attack\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/4/21571?source=see_link\">",
"       \"Patient information: Mitral valve prolapse (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17242780\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with mitral valve prolapse (MVP) may develop a nonarrhythmic complication such as hemodynamically significant mitral regurgitation, heart failure, infective endocarditis, or transient ischemic attack or stroke. The overall risk of serious complications of MVP is approximately 1 percent per year. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mitral valve prolapse is the most common etiology of primary isolated mitral regurgitation (MR), accounting for over 50 percent of cases; it also accounts for over 60 percent of patients with ruptured chordae tendineae. The majority of patients have only trace or mild MR; hemodynamically significant MR is uncommon in MVP, occurring in only 2 to 7 percent of cases. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mitral regurgitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to increasing the likelihood of the need for valve surgery, the presence of moderate to severe MR with MVP has been implicated as a marker for complications such as infective endocarditis, arrhythmias, heart failure, and cardiovascular mortality, including sudden death. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mitral regurgitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mitral regurgitation severity should be formally quantified by comprehensive echocardiography as jet Color Doppler appearance may be misleading. Regurgitant orifice area and volume have prognostic implications.",
"     </li>",
"     <li>",
"      Presence of severe left atrial enlargement and pulmonary hypertension in patients with mitral regurgitation due to MVP are associated with increase in cardiovascular morbidity and mortality.",
"     </li>",
"     <li>",
"      Infective endocarditis occurs at an increased frequency in patients with MVP when compared to those with a normal mitral valve, although the absolute risk of infection is low. Antibiotic prophylaxis is, however, no longer recommended for patients with MVP. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Infective endocarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The association between thromboembolic events and mitral valve prolapse is most likely related to the prevalence of other risk factors for embolism including atrial fibrillation, which may be paroxysmal and asymptomatic. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Transient ischemic attacks and cerebral vascular accidents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      is recommended in patients with unexplained transient ischemic attacks in sinus rhythm with no atrial thrombi. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Recommendations for antithrombotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anticoagulation is recommended in patients with atrial fibrillation or systemic embolism and in those with recurrent transient ischemic attacks despite",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Recommendations for antithrombotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Embolic events in adults with MVP and only mild MR are presumed due to paroxysmal AF and should be treated as in other cases of non-valvular AF. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with MVP and moderate to severe MR, documented AF or embolic events due to presumed paroxysmal AF should be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      anticoagulation (goal INR 2.5, range 2.0 to 3.0). The use of newer oral anticoagulants (direct thrombin and Xa inhibitors) has not been studied in these patients because adults with valvular heart disease were excluded from clinical trials of these agents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2873460\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. Matthew J. Sorrentino for his contributions as an author to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/1\">",
"      Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet 2006; 368:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/2\">",
"      Olson LJ, Subramanian R, Ackermann DM, et al. Surgical pathology of the mitral valve: a study of 712 cases spanning 21 years. Mayo Clin Proc 1987; 62:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/3\">",
"      Zuppiroli A, Rinaldi M, Kramer-Fox R, et al. Natural history of mitral valve prolapse. Am J Cardiol 1995; 75:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/4\">",
"      Avierinos JF, Gersh BJ, Melton LJ 3rd, et al. Natural history of asymptomatic mitral valve prolapse in the community. Circulation 2002; 106:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/5\">",
"      Kim S, Kuroda T, Nishinaga M, et al. Relationship between severity of mitral regurgitation and prognosis of mitral valve prolapse: echocardiographic follow-up study. Am Heart J 1996; 132:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/6\">",
"      Devereux RB, Hawkins I, Kramer-Fox R, et al. Complications of mitral valve prolapse. Disproportionate occurrence in men and older patients. Am J Med 1986; 81:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/7\">",
"      Enriquez-Sarano M, Tajik AJ, Schaff HV, et al. Echocardiographic prediction of left ventricular function after correction of mitral regurgitation: results and clinical implications. J Am Coll Cardiol 1994; 24:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/8\">",
"      Crawford MH, Souchek J, Oprian CA, et al. Determinants of survival and left ventricular performance after mitral valve replacement. Department of Veterans Affairs Cooperative Study on Valvular Heart Disease. Circulation 1990; 81:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/9\">",
"      Freed LA, Levy D, Levine RA, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med 1999; 341:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/10\">",
"      Levy D, Savage D. Prevalence and clinical features of mitral valve prolapse. Am Heart J 1987; 113:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/11\">",
"      Devereux RB, Kramer-Fox R, Kligfield P. Mitral valve prolapse: causes, clinical manifestations, and management. Ann Intern Med 1989; 111:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/12\">",
"      Enriquez-Sarano M, Basmadjian AJ, Rossi A, et al. Progression of mitral regurgitation: a prospective Doppler echocardiographic study. J Am Coll Cardiol 1999; 34:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/13\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/14\">",
"      Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003; 16:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/15\">",
"      Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33:2451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/16\">",
"      Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med 2005; 352:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/17\">",
"      Pizarro R, Bazzino OO, Oberti PF, et al. Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation. J Am Coll Cardiol 2009; 54:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/18\">",
"      Kang DH, Kim JH, Rim JH, et al. Comparison of early surgery versus conventional treatment in asymptomatic severe mitral regurgitation. Circulation 2009; 119:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/19\">",
"      Enriquez-Sarano M, Sinak LJ, Tajik AJ, et al. Changes in effective regurgitant orifice throughout systole in patients with mitral valve prolapse. A clinical study using the proximal isovelocity surface area method. Circulation 1995; 92:2951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/20\">",
"      Topilsky Y, Michelena H, Bichara V, et al. Mitral valve prolapse with mid-late systolic mitral regurgitation: pitfalls of evaluation and clinical outcome compared with holosystolic regurgitation. Circulation 2012; 125:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/21\">",
"      Davies MJ, Moore BP, Braimbridge MV. The floppy mitral valve. Study of incidence, pathology, and complications in surgical, necropsy, and forensic material. Br Heart J 1978; 40:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/22\">",
"      Chesler E, King RA, Edwards JE. The myxomatous mitral valve and sudden death. Circulation 1983; 67:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/23\">",
"      Ribeiro CL, Ginefra P, Albanesi Filho FM, et al. [Prevalence of tricuspid and aortic valve prolapse in patients with mitral valve prolapse]. Arq Bras Cardiol 1989; 53:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/24\">",
"      Come PC, Riley MF, Carl LV, Nakao S. Pulsed Doppler echocardiographic evaluation of valvular regurgitation in patients with mitral valve prolapse: comparison with normal subjects. J Am Coll Cardiol 1986; 8:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/25\">",
"      Yilmaz O, Suri RM, Dearani JA, et al. Functional tricuspid regurgitation at the time of mitral valve repair for degenerative leaflet prolapse: the case for a selective approach. J Thorac Cardiovasc Surg 2011; 142:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/26\">",
"      Weinberger I, Rotenberg Z, Zacharovitch D, et al. Native valve infective endocarditis in the 1970s versus the 1980s: underlying cardiac lesions and infecting organisms. Clin Cardiol 1990; 13:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/27\">",
"      McKinsey DS, Ratts TE, Bisno AL. Underlying cardiac lesions in adults with infective endocarditis. The changing spectrum. Am J Med 1987; 82:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/28\">",
"      Castonguay MC, Burner KD, Edwards WD, et al. Surgical pathology of native valve endocarditis in 310 specimens from 287 patients (1985-2004). Cardiovasc Pathol 2013; 22:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/29\">",
"      MacMahon SW, Roberts JK, Kramer-Fox R, et al. Mitral valve prolapse and infective endocarditis. Am Heart J 1987; 113:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/30\">",
"      D&uuml;ren DR, Becker AE, Dunning AJ. Long-term follow-up of idiopathic mitral valve prolapse in 300 patients: a prospective study. J Am Coll Cardiol 1988; 11:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/31\">",
"      Marks AR, Choong CY, Sanfilippo AJ, et al. Identification of high-risk and low-risk subgroups of patients with mitral-valve prolapse. N Engl J Med 1989; 320:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/32\">",
"      Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/33\">",
"      Devereux RB, Frary CJ, Kramer-Fox R, et al. Cost-effectiveness of infective endocarditis prophylaxis for mitral valve prolapse with or without a mitral regurgitant murmur. Am J Cardiol 1994; 74:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/34\">",
"      Durack DT, Kaplan EL, Bisno AL. Apparent failures of endocarditis prophylaxis. Analysis of 52 cases submitted to a national registry. JAMA 1983; 250:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/35\">",
"      Desimone DC, Tleyjeh IM, Correa de Sa DD, et al. Incidence of infective endocarditis caused by viridans group streptococci before and after publication of the 2007 American Heart Association's endocarditis prevention guidelines. Circulation 2012; 126:60.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson W, Taubert KA, Gewitz M, et al. Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 115 published online April 19, 2007. www.circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.106.183095v1 (Accessed on May 04, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/37\">",
"      Avierinos JF, Brown RD, Foley DA, et al. Cerebral ischemic events after diagnosis of mitral valve prolapse: a community-based study of incidence and predictive factors. Stroke 2003; 34:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/38\">",
"      Gilon D, Buonanno FS, Joffe MM, et al. Lack of evidence of an association between mitral-valve prolapse and stroke in young patients. N Engl J Med 1999; 341:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/39\">",
"      Wolf PA, Sila CA. Cerebral ischemia with mitral valve prolapse. Am Heart J 1987; 113:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/40\">",
"      Nichol, P, Kertesz, A. Two dimensional echocardiographic (2DE) detection of left atrial thrombosis in patient with mitral valve prolapse and strokes. Circulation 1979; 59/60 (Suppl II):18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2648/abstract/41\">",
"      Tse HF, Lau CP, Cheng G. Relation between mitral regurgitation and platelet activation. J Am Coll Cardiol 1997; 30:1813.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8167 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-0970125B04-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_37_2648=[""].join("\n");
var outline_f2_37_2648=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17242780\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MITRAL REGURGITATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21904137\">",
"      Role of quantification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Natural history and role of surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PROLAPSE OF OTHER VALVES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INFECTIVE ENDOCARDITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TRANSIENT ISCHEMIC ATTACKS AND CEREBRAL VASCULAR ACCIDENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Does a relationship exist between stroke and MVP?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Potential mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Recommendations for antithrombotic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17242780\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2873460\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8167\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8167|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/17/34077\" title=\"figure 1\">",
"      MVP complication and MR severity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8167|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/19/35132\" title=\"table 1\">",
"      Valve surgery nonischemic MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/15/29948\" title=\"table 2\">",
"      Antithrombotic Rx in MVP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17719?source=related_link\">",
"      Arrhythmic complications of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13705?source=related_link\">",
"      Definition and diagnosis of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25096?source=related_link\">",
"      Indications for corrective surgery in severe chronic primary mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3476?source=related_link\">",
"      Mitral valve prolapse syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6649?source=related_link\">",
"      Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/4/21571?source=related_link\">",
"      Patient information: Mitral valve prolapse (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32281?source=related_link\">",
"      Secondary prevention for specific causes of ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36697?source=related_link\">",
"      Surgical procedures for severe chronic mitral regurgitation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_37_2649="Acyclovir (systemic): Pediatric drug information";
var content_f2_37_2649=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acyclovir (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?36/40/37512?source=see_link\">",
"    see \"Acyclovir (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/48/38660?source=see_link\">",
"    see \"Acyclovir (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7808291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zovirax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7808292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Acyclovir&reg;;",
"     </li>",
"     <li>",
"      Mylan-Acyclovir;",
"     </li>",
"     <li>",
"      Nu-Acyclovir;",
"     </li>",
"     <li>",
"      ratio-Acyclovir;",
"     </li>",
"     <li>",
"      Teva-Acyclovir;",
"     </li>",
"     <li>",
"      Zovirax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10456715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiviral Agent, Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiviral Agent, Parenteral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11426609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      HSV infection, treatment:",
"     </b>",
"     I.V.: 20 mg/kg/dose every 8 hours for 14-21 days; CNS and disseminated infections: 21 day treatment duration; skin and mucous membrane infections: 14 day treatment duration (CDC, 2010;",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      HSV, chronic suppression following disseminated or CNS infection:",
"     </b>",
"     Limited data available: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     AAP Recommendation (low dose, 6-month-course): 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 8 hours; begin after completion of a 14- to 21-day-course of I.V. therapy dependent upon type of infection; duration of therapy: 6 months (Kimberlin, 2011; Kimberlin, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Alternate dosing (high-dose, 2-year-course) (Tiffany, 2005): Begin after completion of a 21-day-course of I.V. therapy; dosing based on a prospective trial of 16 consecutive neonates (GA: Premature: n=4; term= 12; age at treatment: Neonate: n=14; PNA &gt;30 days: n=1); pharmacokinetic data were used to determine dosing regimen to maintain serum acyclovir concentration above target of 2 mcg/mL; treatment was continued for 2 years in 14 of 16 patients; results showed normal neurodevelopmental outcomes in 69% and normal motor development in 70%; no untoward effects were reported during the study duration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Initial dosing: Approximate dose: 1200-1600 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Preterm neonate: Proportional decrease of full-term initial dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Full term or near term: 400 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance dosing: In the trial, serum acyclovir concentrations were evaluated to assess adequacy of dosing to maintain serum concentrations above the target of 2-3 mcg/mL. Samples were collected 1 hour after a witnessed dose; if the acyclovir serum concentration approached or was below the target; the dose was increased to the next greater 200 mg increment. Serum concentrations were evaluated every 3 months; in order to limit the phlebotomy losses, follow-up serum concentrations were not evaluated outside of routine monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Varicella zoster (chickenpox), treatment:",
"     </b>",
"     I.V.: 10-15 mg/kg/dose every 8 hours for 5-10 days; continue for &ge;48 hours after the last new lesions have appeared (Ogilvie, 1998; Sauerbrei, 2007; Smith, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Manufacturer's labeling: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;50 mL/minute/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     : No adjustments necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     25-50 mL/minute/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     10-25mL/minute/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     0-10 mL/minute/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 50% of the dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alternate dosing: The following adjustments have been recommended (Englund, 1991): I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     0.8-1.1 mg/dL: Administer 20 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     1.2-1.5 mg/dL: Administer 20 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;1.5 mg/dL: Administer 10 mg/kg/dose every 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10456740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/40/37512?source=see_link\">",
"      see \"Acyclovir (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Obese patients should be dosed using ideal body weight.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      HSV neonatal infection, treatment and suppressive therapy in very young infants (independent of HIV status):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment (disseminated, CNS, or skin, eye, or mouth disease): I.V.:  Infants 1-3 months: 20 mg/kg/dose every 8 hours; treatment duration: For cutaneous and mucous membrane infections (skin, eye, or mouth): 14 days; for CNS or disseminated infection: 21 days (CDC, 2009;",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Chronic suppressive therapy: Limited data available: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     AAP Recommendation (low dose, 6-month-course): 300 mg/",
"     <b>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"     </b>",
"     /dose every 8 hours; begin after completion of a  14- to 21-day-course of I.V. therapy dependent upon type of infection; duration of therapy: 6 months (Kimberlin, 2011; Kimberlin, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Alternate dosing (high dose, 2-year-course) (Tiffany, 2005): Begin after completion of a 21 day course of I.V. therapy; dosing based on a prospective trial of 16 consecutive neonates (GA: Premature: n=4; term= 12; age at treatment: Neonate: n=14; PNA &gt;30 days: n=1); pharmacokinetic data were used to determine dosing regimen to maintain serum acyclovir concentration above target of 2-3 mcg/mL; treatment was continued for 2 years in 14 of 16 patients; results showed normal neurodevelopmental outcomes in 69% and normal motor development in 70%; no untoward effects were reported during the study duration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Initial dosing: 400 mg twice daily ; approximate dose: 1200-1600 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Maintenance dosing:",
"     <b>",
"      Note",
"     </b>",
"     : Approximate doses for patients born at term:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Infants 1 to &lt;5 months: 400 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Infants 5 to &lt;9 months: 600 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Infants and Children 9 to &lt;15 months: 800 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Children 15-24 months: 1000 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     <b>",
"      Note:",
"     </b>",
"     In the trial, serum  acyclovir concentrations were evaluated to assess adequacy of dosing to maintain serum concentrations above the target of 2-3 mcg/mL.   Samples were collected 1 hour after a 	witnessed dose; if the acyclovir serum concentration approached or was below the target; the dose was 	increased to the next greater 200 mg increment. Maximum dose: 1200 mg. Serum concentrations were evaluated every 3 months; in order to limit the phlebotomy losses, follow-up serum concentrations were not evaluated outside of routine monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      HSV encephalitis, treatment:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants  and Children 3 months to &lt;12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Non-HIV-exposed/-positive:",
"     </i>",
"     10-15 mg/kg/dose every 8 hours for 14 to 21 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      HIV-exposed/-positive:",
"     </i>",
"     10 mg/kg/dose every 8 hours for 21 days; do not discontinue therapy  until the repeat CSF HSV DNA PCR is negative (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;12 years and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Non-HIV-exposed/-positive:",
"     </i>",
"     10 mg/kg/dose every 8 hours for 14-21 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      HIV-exposed/-positive:",
"     </i>",
"     10 mg/kg/dose every 8 hours for 21 days (CDC, 2009; CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      HSV genital infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     First infection, mild to moderate: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Non-HIV-exposed/-positive:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Children &lt;12 years: 40-80 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided in 3-4 doses per day for 5-10 days; maximum daily dose: 1000 mg/",
"     <b>",
"      day",
"     </b>",
"     (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Children and Adolescents &ge;12 years: 200 mg every 4 hours while awake (5 times daily)",
"     <b>",
"      or",
"     </b>",
"     400 mg 3 times daily for 7-10 days; treatment can be extended beyond 10 days if healing is not complete  (CDC, 2010;",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      HIV-exposed/-positive:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Children &lt;45 kg: 20 mg/kg/dose 3 times daily for 5-14 days; maximum dose: 400 mg (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Children &ge;45 kg and Adolescents: 400 mg 2-3 times daily for 5-14 days (CDC, 2009; CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     First infection, severe (independent of HIV status): I.V.: Children and Adolescents &ge;12 years: 5 mg/kg/dose every 8 hours for 5-7 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Recurrent infection: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children &lt;12 years: 10 mg/kg/dose every 8 hours for up to 12 months; maximum daily dose: 1000 mg/",
"     <b>",
"      day",
"     </b>",
"     ; re-evaluate after 12 months (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children and Adolescents &ge;12 years: 200 mg every 4 hours while awake (5 times daily)  for 5 days",
"     <b>",
"      or",
"     </b>",
"     800 mg twice daily  for 5 days",
"     <b>",
"      or",
"     </b>",
"     800 mg 3 times daily for 2 days  (CDC, 2010;",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Suppression, chronic: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Non-HIV-exposed/-positive:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Children &lt;12 years: 40-80 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in 3 divided doses for up to 12 months; maximum daily dose: 1000 mg/",
"     <b>",
"      day",
"     </b>",
"     (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Children and Adolescents &ge;12 years: 400 mg twice daily for up to 12 months (CDC, 2010;",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      HIV-exposed/-positive:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Infants and Children: 20 mg/kg/dose 2 times daily; maximum dose: 400 mg (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Adolescents: 400 mg twice daily (CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      HSV gingivostomatitis  (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Mild, symptomatic: Oral: Infants and Children: 20 mg/kg/dose 3 times daily for 5-10 days; maximum dose: 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Moderate to severe, symptomatic: I.V.: Infants and Children: 5-10 mg/kg/dose every 8 hours; switch to oral therapy once lesions begin to regress",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      HSV, herpes labialis (cold sore) recurrent, chronic suppressive therapy:",
"     </b>",
"     Oral: Children: 30 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in 3 divided doses for up to 12 months; maximum daily dose: 1000 mg/",
"     <b>",
"      day",
"     </b>",
"     ; re-evaluate after 12 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      HSV mucosal or cutaneous infection (immunocompromised host):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     I.V.: Infants, Children, and Adolescents: 10 mg/kg/dose every 8 hours for 7-14 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Oral: Children &ge;2 years and Adolescents: 1000 mg/",
"     <b>",
"      day",
"     </b>",
"     in 3-5 divided doses for 7-14 days; some suggest the maximum daily dose should not exceed 80 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009;",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Suppression, chronic (cutaneous, ocular) episodes: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants and Children (HIV-exposed/-positive): 20 mg/kg/dose twice daily for 5-14 days; maximum dose: 400 mg (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children and Adolescents &ge;12 years (independent of HIV status): 400 mg twice daily for up to 12 months (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      HSV progressive or disseminated infection, treatment (immunocompromised host) including HIV-exposed/-positive:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Non-HIV-exposed/-positive: Infants, Children, and Adolescents: I.V.:  10 mg/kg/dose every 8 hours for 7-21 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HIV-exposed/-positive: Infants, Children, and Adolescents: I.V.: 10 mg/kg/dose every 8 hours for 21 days (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      HSV prophylaxis; immunocompromised hosts, seropositive:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Hematopoietic stem cell transplant (HSCT) in seropositive recipient",
"     </i>",
"     (Tomblyn, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Prevention of early reactivation:",
"     <b>",
"      Note:",
"     </b>",
"     Begin at conditioning and continue until engraftment or resolution of mucositis; whichever is longer (~30 days post-HSCT)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Infants and Children &lt;40 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     I.V.: 250 mg/",
"     <b>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"     </b>",
"     /dose every 8 hours",
"     <b>",
"      or",
"     </b>",
"     125 mg/",
"     <b>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"     </b>",
"     /dose every 6 hours; maximum daily dose: 80 mg/kg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Oral: 60-90 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in 2-3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Children and Adolescents &ge;40 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     I.V.: 250 mg/",
"     <b>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"     </b>",
"     /dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Oral: 400-800 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Prevention of late reactivation:",
"     <b>",
"      Note:",
"     </b>",
"     Treatment during first year after HSCT.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Infants and Children &lt;40 kg: Oral: 60-90 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in 2-3 divided doses; maximum daily dose: 800 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Children and Adolescents &ge;40 kg: Oral: 800 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      HIV-exposed/-positive, prevention of HSV reactivation:",
"     </i>",
"     Oral: Infants and Children: 20 mg/kg/dose twice daily, maximum dose: 400 mg (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Other immunocompromised hosts who are HSV seropositive:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     I.V.: Infants, Children, and Adolescents: 5 mg/kg/dose every 8 hours during period of risk (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Oral: Children &ge;2 years and Adolescents: 200 mg every 4 hours while awake (5 doses daily)",
"     <b>",
"      or",
"     </b>",
"     200 mg every 8 hours (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Varicella zoster (chickenpox or shingles), prophylaxis (HIV-exposed/-positive):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants and Children: 20 mg/kg/dose 4 times daily for 5-7 days; maximum dose: 800 mg; consider use if &gt;96 hours postexposure or if VZV-immune globulin is not available (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adolescents: 800 mg 5 times daily for 5 days (CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Varicella zoster (chickenpox), treatment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Immunocompetent host:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Ambulatory therapy: Oral: Children &ge;2 years and Adolescents: 20 mg/kg/dose 4 times daily for 5 days; maximum daily dose: 3200 mg/",
"     <b>",
"      da",
"     </b>",
"     y (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Hospitalized patient: I.V.: Children &ge;2 years and Adolescents: 10 mg/kg/dose",
"     <b>",
"      or",
"     </b>",
"     500 mg/",
"     <b>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"     </b>",
"     /dose every 8 hours for 7-10 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Immunocompromised host (non-HIV-exposed/-positive):",
"     </i>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants: 10 mg/kg/dose every 8 hours for 7-10 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children and Adolescents: 500 mg/",
"     <b>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"     </b>",
"     /dose every 8 hours for 7-10 days; some experts recommend 10 mg/kg/dose every 8 hours (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      HIV-exposed/-positive:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Mild, uncomplicated disease and no or moderate immune suppression: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Infants and Children: 20 mg/kg/dose 4 times daily for 7-10 days or until no new lesions for 48 hours; maximum dose:  800 mg  (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Adolescents: 20 mg/kg/dose 5 times daily for 5-7 days, maximum dose: 800  mg (CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Severe, complicated disease or severe immune suppression: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Infants: 10 mg/kg/dose every 8 hours for 7-10 days or until no new lesions for 48 hours (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Children: 10 mg/kg/dose",
"     <b>",
"      or",
"     </b>",
"     500 mg/",
"     <b>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"     </b>",
"     /dose every 8 hours for 7-10 days or until no new lesions for 48 hours (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Adolescents: 10-15 mg/kg/dose every 8 hours for 7-10 days (CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Varicella zoster (shingles), treatment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Immunocompetent host:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Ambulatory therapy: Oral: Children &ge;12 years and Adolescents: 800 mg every 4 hours (5 doses per day) for 5-7 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Hospitalized patient: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Infants: 10 mg/kg/dose every 8 hours for 7-10 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Children and Adolescents: 500 mg/",
"     <b>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"     </b>",
"     /dose every 8 hours for 7-10 days; some experts recommend 10 mg/kg/dose every 8 hours (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Immunocompromised host (non-HIV-exposed/-positive):",
"     </i>",
"     I.V.: Infants, Children, and Adolescents: 10 mg/kg/dose every 8 hours for 7-10 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      HIV-exposed/-positive:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Mild, uncomplicated disease and no or moderate immune suppression: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Infants and Children: 20 mg/kg/dose 4 times daily for 7-10 days; maximum dose: 800 mg; consider longer course if resolution of lesions is slow (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Adolescents: 800 mg 5 times daily for 5-7 days (CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Severe immune suppression or complicated disease; trigeminal nerve involvement, extensive multidermatomal zoster or extensive cutaneous lesions or visceral involvement: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Infants: 10 mg/kg/dose every 8 hours until resolution of cutaneous lesions and visceral disease clearly begins, then convert to oral therapy to complete a 10-14 day total course of therapy (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Children: 10 mg/kg/dose",
"     <b>",
"      or",
"     </b>",
"     500 mg/",
"     <b>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"     </b>",
"     /dose every 8 hours until resolution of cutaneous lesions and visceral disease clearly begins, then convert to oral therapy to complete a 10-14 day total course of therapy (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Adolescents: 10-15 mg/kg/dose every 8 hours until clinical improvement is evident, then convert to oral therapy to complete a 10-14 day total course of therapy (CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Varicella zoster, acute retinal necrosis, treatment (HIV-exposed/-positive):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Initial treatment:  I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants: 10-15 mg/kg/dose every 8 hours for 10-14 days followed by oral acyclovir (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children: 10-15 mg/kg/dose",
"     <b>",
"      or",
"     </b>",
"     500 mg/",
"     <b>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"     </b>",
"     /dose every 8 hours for 10-14 days followed by oral acyclovir or valacyclovir (if old enough to receive adult dose) (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents: 10 mg/kg/dose every 8 hours for 10-14 days, followed by oral valacyclovir (CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance treatment; begin after 10-14 day course of I.V. acyclovir: Oral: Infants and Children: 20 mg/kg/dose every 8 hours for a total duration of therapy of 4-6 weeks (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      HSV encephalitis:",
"     </b>",
"     I.V.: 10 mg/kg/dose every 8 hours for 10 days; 10-15 mg/kg/dose every 8 hours for 14-21 days has also been reported",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      HSV genital infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: Immunocompetent: Initial episode, severe: 5 mg/kg/dose every 8 hours for 5-7 days",
"     <b>",
"      or",
"     </b>",
"     5-10 mg/kg/dose every 8 hours for 2-7 days, follow with oral therapy to complete at least 10 days of therapy (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Initial episode: 200 mg every 4 hours while awake (5 times/day)",
"     <b>",
"      or",
"     </b>",
"     400 mg 3 times daily for 7-10 days (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Recurrence: 200 mg every 4 hours while awake (5 times/day) for 5 days; begin at earliest signs of disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Alternatively, the following regimens are also recommended by the CDC: 400 mg 3 times daily for 5 days; 800 mg twice daily for 5 days; 800 mg 3 times daily for 2 days (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Chronic suppression: 400 mg twice daily (CDC 2010) or 200 mg 3-5 times daily, for up to 12 months followed by re-evaluation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      HSV mucocutaneous:",
"     </b>",
"     Immunocompromised: Treatment: I.V.:  5 mg/kg/dose every 8 hours for 7 days (Leflore, 2000); dosing for up to 14 days also reported",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Varicella Zoster (chickenpox):",
"     </b>",
"     Begin treatment within the first 24 hours of rash onset:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: &gt;40 kg (immunocompetent): 800 mg/dose 4 times daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Manufacturer&rsquo;s labeling (immunocompromised): 10 mg/kg/dose every 8 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     AIDS",
"     <i>",
"      info",
"     </i>",
"     guidelines (immunocompromised): 10-15 mg/kg/dose every 8 hours for 7-10 days (CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Herpes zoster (shingles):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Immunocompetent: Oral: 800 mg every 4 hours (5 times daily) for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Immunocompromised: I.V.: 10 mg/kg/dose",
"     <b>",
"      or",
"     </b>",
"     500 mg/",
"     <b>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"     </b>",
"     /dose every 8 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Oral: Children, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;25 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-25 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Normal dosing regimen 200 mg every 4 hours or 400 mg every 12 hours: No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Normal dosing regimen 800 mg every 4 hours: Administer 800 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Normal dosing regimen 200 mg every 4 hours or 400 mg every 12 hours: Administer 200 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Normal dosing regimen 800 mg every 4 hours: Administer 800 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Intermittent hemodialysis (IHD): Administer after hemodialysis on dialysis days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     I.V.: Infants, Children, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     25-50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-25 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     :  Administer 50% of dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Intermittent hemodialysis (IHD):  Administer 50% of dose; administer after hemodialysis on dialysis days (Aronoff, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Peritoneal dialysis (PD): Administer 50% of normal dose once daily; no supplemental dose needed (Aronoff, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Continuous renal replacement therapy (CRRT):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Infants, Children, and Adolescents: I.V.: 10 mg/kg/dose every 12 hours (Aronoff, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Adults: Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment (Heintz, 2009; Trotman, 2005):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     CVVH: I.V.: 5-10 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     CVVHD/CVVHDF: I.V.: 5-10 mg/kg every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     <b>",
"      Note:",
"     </b>",
"     The higher end of dosage range (eg, 10 mg/kg every 12 hours for CVVHDF) is recommended for viral meningoencephalitis and varicella zoster virus infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     There are no dosage adjustments provided in the manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7901193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zovirax&reg;: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium [strength expressed as base]: 500 mg, 1000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium [strength expressed as base, preservative free]: 50 mg/mL (10 mL, 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 200 mg/5 mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zovirax&reg;: 200 mg/5 mL (473 mL) [banana flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 400 mg, 800 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zovirax&reg;: 400 mg, 800 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7908323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10456804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: May administer with or without food; shake suspension well before use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Reconstitute vial for injection with SWI; do not use SWI containing parabens or benzyl alcohol; further dilute to a final concentration &le;7 mg/mL and administer by slow I.V. infusion over at least 1 hour; rapid infusion is associated with nephrotoxicity due to crystalluria and renal tubular damage and should be avoided. In patients who require fluid restriction, a concentration of up to 10 mg/mL has been infused; concentration &gt;10 mg/mL increases the risk of phlebitis. Avoid I.V. push, I.M., or SubQ administration.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F7808315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Incompatible",
"     </b>",
"     with blood products and protein-containing solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amikacin, amphotericin B cholesteryl sulfate complex, ampicillin, anidulafungin, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime,  chloramphenicol, cimetidine, clindamycin,  dexamethasone sodium phosphate, dimenhydrinate, docetaxel, doripenem, doxorubicin liposome, doxycycline, droperidol, erythromycin lactobionate, etoposide phosphate, famotidine, fentanyl, filgrastim, fluconazole, gallium nitrate, heparin, hydrocortisone sodium succinate, hydromorphone, imipenem/cilastatin, linezolid, lorazepam, magnesium sulfate, melphalan, methylprednisolone sodium succinate, metronidazole, milrinone, multivitamins, nafcillin, nalbuphine, oxacillin, paclitaxel, pemetrexed, penicillin G potassium, pentobarbital, piperacillin, potassium chloride, propofol, ranitidine, remifentanil, sodium bicarbonate, sulfamethoxazole and trimethoprim, teniposide, theophylline, thiotepa, tobramycin, vancomycin, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amifostine, amsacrine, aztreonam, caffeine citrate, cefepime, cyclosporine, dobutamine, dopamine, fludarabine, foscarnet, gemcitabine, idarubicin, levofloxacin, ondansetron, pantoprazole, piperacillin/tazobactam, sargramostim, TrophAmine&reg;, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Caspofungin, cefepime, ceftriaxone, cisatracurium, diltiazem, diphenhydramine, gentamicin, granisetron, meperidine, meropenem, metoclopramide, morphine, tacrolimus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Caffeine citrate, ceftriaxone, pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10456725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Store capsules, tablets, and oral suspension at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); protect capsules and tablets from moisture and dispense in a tightly closed container.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Store intact vials at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F). Reconstituted parenteral solutions remain stable for 12 hours at room temperature. Do not refrigerate reconstituted solutions or solutions diluted for infusion as they may precipitate. Once diluted for infusion, use within 24 hours. Incompatible with blood products and protein-containing solutions.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10456716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Treatment of initial and prophylaxis of recurrent mucosal and cutaneous herpes simplex (HSV 1 and HSV 2) infections in immunocompromised patients (FDA approved in all ages); treatment of severe initial episodes of herpes genitalis in immunocompetent patients (FDA approved in ages &ge;12 years and adults); treatment of herpes simplex encephalitis, including neonatal herpes simplex virus (FDA approved in all ages); treatment of varicella-zoster virus (VZV) infections in immunocompromised patients (FDA approved in all ages)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Treatment of chickenpox (varicella) in immunocompetent patients (FDA approved in ages &ge;2 years and adults); treatment of initial episodes and prophylaxis of recurrent herpes simplex (HSV 2, genital herpes) and acute treatment of herpes zoster (shingles) (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Has also been used for treatment of varicella-zoster infections in healthy, nonpregnant persons &gt;13 years of age, children &gt;12 months of age who have a chronic skin or lung disorder or are receiving long-term aspirin therapy, and immunocompromised patients; oral therapy has also been used for suppression following parenteral treatment of neonatal HSV infection",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7808290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Acyclovir may be confused with ganciclovir, Retrovir&reg;, valacyclovir",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zovirax&reg; may be confused with Doribax&reg;, Valtrex&reg;, Zithromax&reg;, Zostrix&reg;, Zyloprim&reg;, Zyvox&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F7808310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oral:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Parenteral:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Hives, itching, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver function tests increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Inflammation at injection site, phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Acute renal failure, BUN increased, creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      All forms:",
"     </b>",
"     Rare but  important or life-threatening: Abdominal pain, aggression, agitation, anemia, anorexia, ataxia, coma, confusion, consciousness decreased, delirium, desquamation, disseminated intravascular coagulopathy (DIC), dizziness, dysarthria, encephalopathy, fatigue, fever, gastrointestinal distress, hallucinations, hematuria, hemolysis, hepatitis, hyperbilirubinemia, hypotension, insomnia, jaundice, leukocytoclastic vasculitis, leukocytosis, leukopenia, lymphadenopathy, mental depression, myalgia, neutrophilia, pain, psychosis, renal failure, renal pain, seizure, somnolence, sore throat, thrombocytopenia, thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), thrombocytosis, visual disturbances",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10456717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acyclovir, valacyclovir, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10456719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution in patients with underlying neurologic disease, significant hypoxia, or hepatic or electrolyte abnormalities; with I.V. therapy, patients (~1%) can exhibit encephalopathic changes, including lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, and coma.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10456718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     HSV and VZV with reduced susceptibility to acyclovir have been isolated from immunocompromised patients, especially patients with advanced HIV disease. Thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) has been reported in immunocompromised patients receiving acyclovir. Renal failure, in some cases resulting in death, has been reported  with acyclovir use; dehydration, pre-existing renal disease, and nephrotoxic drugs increase risk; use with caution in patients with renal disease, dehydration, or those receiving other nephrotoxic agents; dosage should be reduced in patients with renal impairment. Maintain adequate hydration;  dilute I.V. product appropriately and infuse over 1 hour to prevent acyclovir crystal accumulation in renal tubules.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7911154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May increase the serum concentration of Acyclovir-Valacyclovir. Acyclovir-Valacyclovir may increase the serum concentration of Mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: Acyclovir-Valacyclovir may decrease the excretion of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Acyclovir-Valacyclovir may enhance the CNS depressant effect of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zoster Vaccine: Acyclovir-Valacyclovir may diminish the therapeutic effect of Zoster Vaccine.  Management: When possible, discontinue antiviral agents with anti-zoster activity (i.e., acyclovir, valacyclovir, famciclovir) for at least 24 hours prior to and 14 days after receiving a live attenuated zoster vaccine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10456724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food does not appear to affect absorption.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7908326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7908327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. Acyclovir has been shown to cross the human placenta (Henderson, 1992). Results from a pregnancy registry, established in 1984 and closed in 1999, did not find an increase in the number of birth defects with exposure to acyclovir when compared to those expected in the general population. However, due to the small size of the registry and lack of long-term data, the manufacturer recommends using during pregnancy with caution and only when clearly needed. Acyclovir may be appropriate for the treatment of genital herpes in pregnant women (CDC, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10456805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urinalysis, BUN, serum creatinine, urine output; liver enzymes, CBC; neutrophil count at least twice weekly in neonates receiving acyclovir 60 mg/kg/day I.V.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10456726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits DNA synthesis and viral replication by competing with deoxyguanosine triphosphate for viral DNA polymerase and by incorporation into viral DNA",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10456727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Oral: 15% to 30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Widely distributed throughout the body including brain, kidney, lungs, liver, spleen, muscle, uterus, vagina, and the CSF; CSF acyclovir concentration is 50% of serum concentration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Neonates to 3 months of age: 28.8 L/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 1-2 years: 31.6 L/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 2-7 years: 42 L/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &lt;9% to 33%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Converted by viral enzymes to acyclovir monophosphate, and further converted to diphosphate then triphosphate (active form) by cellular enzymes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Oral: 10% to 20%; decreases with increasing dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, terminal phase:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neonates: 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 1-12 years: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 2-3.5 hours (with normal renal function); hemodialysis: ~5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: Oral: Within 1.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Primary route is the kidney with 60% to 90% of a dose excreted unchanged in the urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dialysis: Hemodialysis removes ~60% of dose while removal by peritoneal dialysis is to a lesser extent",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F16027518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/48/38660?source=see_link\">",
"      see \"Acyclovir (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral doses may be taken with food. Maintain adequate hydration, unless instructed to restrict fluid intake. May cause nausea, vomiting, lightheadedness, dizziness, headache, fever, or muscle pain. Report any change in urination (difficulty urinating, dark colored or concentrated urine), persistent lethargy, acute headache, severe nausea or vomiting, confusion or hallucinations, rash, or respiratory difficulty. If used for genital HSV infection: This is not a cure for herpes, nor will this medication reduce the risk of transmission to others when lesions are present; avoid sexual intercourse when visible lesions are present.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F16113203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium content of 1 g: 4.2 mEq",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Infectious Diseases, &ldquo;The Use of Oral Acyclovir in Otherwise Healthy Children With Varicella,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1993, 91(3):674-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/37/2649/abstract-text/8382784/pubmed\" id=\"8382784\" target=\"_blank\">",
"        8382784",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/37/2649/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations From CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009a, 58(RR-4):1-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/37/2649/abstract-text/19357635/pubmed\" id=\"19357635\" target=\"_blank\">",
"        19357635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/37/2649/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Englund JA, Fletcher CV, and Balfour HH Jr, &ldquo;Acyclovir Therapy in Neonates,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1991, 119(1 Pt 1):129-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/37/2649/abstract-text/2066845 /pubmed\" id=\"2066845 \" target=\"_blank\">",
"        2066845",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gartner LM, Morton J, Lawrence RA, et al, \"Breastfeeding and the Use of Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2005, 115(2):496-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/37/2649/abstract-text/15687461/pubmed\" id=\"15687461\" target=\"_blank\">",
"        15687461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, and Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/37/2649/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Henderson GI, Hu ZQ, Johnson RF, et al, \"Acyclovir Transport by the Human Placenta,\"",
"      <i>",
"       J Lab Clin Med",
"      </i>",
"      , 1992, 120(6):885-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/37/2649/abstract-text/1453110/pubmed\" id=\"1453110\" target=\"_blank\">",
"        1453110",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kimberlin DW and Baley J, \"Guidance on Management of Asymptomatic Neonates Born to Women With Active Genital Herpes Lesions,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2013, 131(2):e635-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/37/2649/abstract-text/23359576/pubmed\" id=\"23359576\" target=\"_blank\">",
"        23359576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kimberlin DW, Lin CY, Jacobs RF, et al, &ldquo;Safety and Efficacy of High-Dose Intravenous Acyclovir in the Management of Neonatal Herpes Simplex Virus Infections,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(2):230-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/37/2649/abstract-text/11483782/pubmed\" id=\"11483782\" target=\"_blank\">",
"        11483782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kimberlin DW, Whitley RJ, Wan W, et al, \"Oral Acyclovir Suppression and Neurodevelopment After Neonatal Herpes,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(14):1284-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/37/2649/abstract-text/21991950/pubmed\" id=\"21991950\" target=\"_blank\">",
"        21991950",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ogilvie MM, \"Antiviral Prophylaxis and Treatment in Chickenpox. A Review Prepared for the UK Advisory Group on Chickenpox on Behalf of the British Society for the Study of Infection,\"",
"      <i>",
"       J Infect",
"      </i>",
"      , 1998, 36(Suppl 10:31-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/37/2649/abstract-text/9514106/pubmed\" id=\"9514106\" target=\"_blank\">",
"        9514106",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2012 Report of the Committee on Infectious Diseases",
"      </i>",
"      , \"Antibacterial Drugs Dosage Tables,\" 29th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2012, 808-16. Available at file://aapredbook.aappublications.org/cgi/content/full",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sauerbrei A and Wutzler P, \"Herpes Simplex and Varicella-Zoster Virus Infections During Pregnancy: Current Concepts of Prevention, Diagnosis and Therapy. Part 2: Varicella-Zoster Virus Infections,\"",
"      <i>",
"       Med Microbiol Immunol",
"      </i>",
"      , 2007, 196(2):95-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/37/2649/abstract-text/17180380/pubmed\" id=\"17180380\" target=\"_blank\">",
"        17180380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith CK and Arvin AM, \"Varicella in the Fetus and Newborn,\"",
"      <i>",
"       Semin Fetal Neonatal Med",
"      </i>",
"      , 2009, 14(4):209-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/37/2649/abstract-text/19097954/pubmed\" id=\"19097954\" target=\"_blank\">",
"        19097954",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tiffany KF, Benjamin DK Jr, Palasanthiran P, et al, \"Improved Neurodevelopmental Outcomes Following Long-Term High-Dose Oral Acyclovir Therapy in Infants With Central Nervous System and Disseminated Herpes Simplex Disease,\"",
"      <i>",
"       J Perinatol",
"      </i>",
"      , 2005, 25(3):156-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/37/2649/abstract-text/15605069/pubmed\" id=\"15605069\" target=\"_blank\">",
"        15605069",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tomblyn M, Chiller T, Einsele H, et al, \"Guidelines for Preventing Infectious Complications Among Hematopoietic Cell Transplantation Recipients: A Global Perspective,\"",
"      <i>",
"       Biol Blood Marrow Transplant",
"      </i>",
"      , 2009, 15(10):1143-238.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/37/2649/abstract-text/19747629/pubmed\" id=\"19747629\" target=\"_blank\">",
"        19747629",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, \"Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41:1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/37/2649/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15938 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-CAE323FBD7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_37_2649=[""].join("\n");
var outline_f2_37_2649=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7808291\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7808292\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10456715\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11426609\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10456740\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7901193\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908323\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10456804\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7808315\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10456725\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10456716\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7808290\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7808310\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10456717\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10456719\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10456718\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298682\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7911154\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10456724\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908326\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908327\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10456805\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10456726\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10456727\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16027518\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16113203\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15938\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15938|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_international\" href=\"UTD.htm?17/42/18081?source=related_link\">",
"      Acyclovir (ophthalmic): International drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/40/37512?source=related_link\">",
"      Acyclovir (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/48/38660?source=related_link\">",
"      Acyclovir (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/27/1460?source=related_link\">",
"      Acyclovir (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/60/40899?source=related_link\">",
"      Acyclovir (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/51/9011?source=related_link\">",
"      Acyclovir (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_37_2650="End of life considerations for heart failure patients";
var content_f2_37_2650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   End of life considerations for heart failure patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/37/2650/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/37/2650/contributors\">",
"     Sarah J Goodlin, MD, FACC, FAAHPM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/37/2650/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/37/2650/contributors\">",
"     Sharon A Hunt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/37/2650/contributors\">",
"     R Sean Morrison, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/37/2650/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/37/2650/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/37/2650/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure (HF) is a common and frequently life-limiting illness with increasing prevalence, particularly among the growing population of elderly persons. Nearly 300,000 persons in the United States die with HF annually, and HF was the primary cause of death for over 60,000 persons in 2006 in the United States. Hospitalization rates for decompensated HF are high and one-third or more of HF patients die within a year of a hospitalization for HF [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/1\">",
"     1",
"    </a>",
"    ]. The average life expectancy following diagnosis of HF is under six years. However, the course of HF is variable, and some persons live 10 years or more years with good medication response and dietary and lifestyle management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4058?source=see_link\">",
"     \"Prognosis of heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=see_link\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Variability in the course of HF makes identifying the end of life in patients with HF challenging and limited data are available to guide end of life care. Nonetheless, clinicians and researchers have called for palliative care for advanced HF [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/2\">",
"     2",
"    </a>",
"    ], and major cardiology society guidelines recognize the need for palliative care for HF patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     IDENTIFICATION OF END-STAGE HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with advanced or end-stage HF have marked symptoms of dyspnea, fatigue or symptoms relating to end-organ hypoperfusion at rest or with minimal exertion despite maximal medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/2\">",
"     2",
"    </a>",
"    ]. This description conforms to stage D and the advanced phase of Stage C HF as defined in the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    HF guidelines (",
"    <a class=\"graphic graphic_algorithm graphicRef57809 \" href=\"UTD.htm?1/38/1637\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/4\">",
"     4",
"    </a>",
"    ]. Persons with advanced HF typically have frequent admissions to the hospital or emergency department with decompensation and volume overload. Patients with advanced HF who comply with self-care management have rates of hospitalization and other events comparable to less ill HF patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation of the patient with heart failure or cardiomyopathy\", section on 'Definition and classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The challenge for a clinician evaluating a patient who appears to have advanced HF is whether there are remediable interventions, adjustments to medications, or other therapies that might improve the patient's function, or whether the patient truly has end-stage disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/2\">",
"     2",
"    </a>",
"    ]. Heart failure patients may have dramatic worsening of functional status and then impressive recovery to a plateau of reasonable function with medical therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    device or surgical interventions.",
"   </p>",
"   <p>",
"    Clinicians should evaluate the HF patient with apparently refractory HF for high sodium intake, noncompliance with HF treatments, sleep disordered breathing (SDB), occult ischemia, deleterious medications, and other insults that may have contributed to the poor status. In addition, HF treatment should be reevaluated to maximize evidence-based therapies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=see_link&amp;anchor=H4#H4\">",
"     \"Evaluation of acute decompensated heart failure\", section on 'Identification of precipitating factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=see_link\">",
"     \"Cheyne-Stokes breathing and obstructive sleep apnea in heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link&amp;anchor=H38#H38\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'Drugs to avoid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specialized strategies are considered for patients with refractory HF, including continuous intravenous positive inotropic therapy, hemofiltration, cardiac transplantation, mechanical circulatory support, and high risk revascularization (",
"    <a class=\"graphic graphic_table graphicRef68693 \" href=\"UTD.htm?15/22/15724\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4743?source=see_link\">",
"     \"Management of refractory heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=see_link\">",
"     \"Indications and contraindications for cardiac transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37785?source=see_link\">",
"     \"Intermediate- and long-term mechanical cardiac support\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35143?source=see_link\">",
"     \"Surgical management of heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3780922\">",
"    <span class=\"h2\">",
"     Estimation of prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identifying patients likely to die soon from HF is challenging, even when using predictive tools and models [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/7\">",
"     7",
"    </a>",
"    ]. Even patients at high risk of dying in a six-month time frame may live one to two years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/8\">",
"     8",
"    </a>",
"    ]. Three or more hospitalizations for HF and age over 85 years were associated with one year or less survival in one retrospective analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/9\">",
"     9",
"    </a>",
"    ]. Models and tools are available to assist clinicians with prognostic estimates [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/10,11\">",
"     10,11",
"    </a>",
"    ], although at best these provide a range or likelihood of a given life-expectancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=see_link\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4058?source=see_link\">",
"     \"Prognosis of heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment and prognosis of diastolic heart failure\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3781077\">",
"    <span class=\"h1\">",
"     COURSE TO DEATH IN HF PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The course to death for HF patients varies with illness severity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/12,13\">",
"     12,13",
"    </a>",
"    ] as well as the degree of adherence to evidence-based HF therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. With meticulous management in HF programs, patients with advanced disease may live five years or longer [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4058?source=see_link\">",
"     \"Prognosis of heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary edema or severe congestion is rare in dying HF patients receiving expert HF management, thus these should be treated and not accepted as usual. Sudden cardiac death (SCD) predominates as the cause of death for persons with less advanced or less symptomatic HF, where as progressive HF with hypotension, end-organ hypoperfusion, or metabolic derangement is a more common cause of death for persons with advanced HF managed in academic HF programs [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], although SCD also occurs in advanced HF [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/19\">",
"     19",
"    </a>",
"    ]. SCD in patients with advanced HF is often associated with severe bradycardia or pulseless electrical activity not responsive to cardioversion or pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatments such as beta blockers that block or reduce neurohormonal activation in HF reduce the incidence of SCD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=see_link&amp;anchor=H12#H12\">",
"     \"Ventricular arrhythmias in heart failure and cardiomyopathy\", section on 'Effect of HF therapy on ventricular arrhythmia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Heart failure patients often have severe functional compromise with limitations in activities of daily living for a year or more prior to death [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/21\">",
"     21",
"    </a>",
"    ]. Loss of ability to perform usual activities, social isolation, shortness of breath, anxiety and having to cope with uncertainty were issues identified in a review of qualitative studies of HF patients confronting the end of life [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/22\">",
"     22",
"    </a>",
"    ]. In one study, many patients hospitalized with NYHA Class IV HF were concerned about avoiding burdening their family, yet even more identified avoiding life support if there was no hope of meaningful recovery and receiving honest information from their doctor as important when considering the end of their lives [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     COMMUNICATION WITH THE PATIENT AND FAMILY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discussions with the patient and family (or caregiver) about quality of life and prognosis are recommended as part of HF management in a 2004 consensus statement [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/2\">",
"     2",
"    </a>",
"    ], in the 2010 HFSA Heart Failure management guideline and in the 2009",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    chronic heart failure guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/4,24\">",
"     4,24",
"    </a>",
"    ]. Discussions with patients about their prognosis differ depending on the phase of their illness and co-morbidities. However, an important component of the conversation is acknowledgment that death comes earlier for HF patients than others.",
"   </p>",
"   <p>",
"    To ease an ultimate discussion of \"end of life,\" the life-limiting nature of HF should be acknowledged with patients and families early in care, while simultaneously planning with patients to optimize therapy to improve function and extend life as appropriate for their values and preferences [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients with HF should have a plan for management of possible SCD at any point in their illness.",
"   </p>",
"   <p>",
"    Talking with a patient who is approaching the end of life about their poor prognosis is a \"bad news\" conversation, and should be structured as such [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/25\">",
"     25",
"    </a>",
"    ]. A majority of HF patients overestimate their life expectancy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/26\">",
"     26",
"    </a>",
"    ]. Many patients are surprised to learn that they will die from HF, because they have not perceived their illness as life-limiting.",
"   </p>",
"   <p>",
"    A basic principle to guide communication is \"Ask-Tell-Ask:\"",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ask what the patient understands and what they want to know",
"     </li>",
"     <li>",
"      Tell the answers to their queries and correct misunderstandings",
"     </li>",
"     <li>",
"      Tell information you feel is critical to decisions about care",
"     </li>",
"     <li>",
"      Ask what questions they have and confirm their understanding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The conversation should end by explaining a plan for the next steps. The uncertainty of the individual's course and length of life should be acknowledged as should the clinicians' commitment to providing care or continuity with other providers. Prognostic estimates should be presented as a range of time, with a qualifying statement that some people live longer and some shorter than the range. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4058?source=see_link&amp;anchor=H13#H13\">",
"     \"Prognosis of heart failure\", section on 'Predictive models'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues for HF patients and their families differ depending upon illness severity and comorbidities as well as age and personal attitudes and beliefs. Thus, ongoing discussions with patients and families should recur with new disease developments and changes in status. When possible, discussions regarding end of life care should be initiated while the patient is still capable of participating in decision-making.",
"   </p>",
"   <p>",
"    Planning care is critical, and can be framed as \"hope for the best and prepare for the worst\" [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/27\">",
"     27",
"    </a>",
"    ]. The scope of plans is broad and should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identification of an approach to care (hospital versus home care or hospice, for example)",
"     </li>",
"     <li>",
"      Identification of goals (continued interventions to maximize function or length of life versus simplifying treatment and focusing on managing symptoms)",
"     </li>",
"     <li>",
"      A plan to manage current interventions to achieve goals, including each medication and device",
"     </li>",
"     <li>",
"      Assistance for family and care givers in delivering care",
"     </li>",
"     <li>",
"      Resources for spiritual and emotional support for patient and family",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Honest communication and decision making with patients and their families can smooth the path toward the end of life. A clear approach to care should be chosen, and the patient and family should have instructions for how to respond to clinical events such as pulmonary edema and SCD. Patient decisions about treatment, including hospice, resuscitation, and implantable cardioverter defibrillator (ICD) use (see",
"    <a class=\"local\" href=\"#H13711359\">",
"     'ICD deactivation'",
"    </a>",
"    below), should be re-addressed often because decisions may change over time [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients will prefer to try to live as long as possible. In this situation, clear goals can be set (eg, \"another visit with family\") and the \"hope for the best, plan for the worst\" dichotomy should be followed to allow the patient to attend to affairs and identify conditions under which the he or she would no longer wish life to be prolonged (eg, \"unable to communicate with family or friends\"). Even while working with the patient to prolong life, the conversation about dying should be framed to identify the patient&rsquo;s and family&rsquo;s preference for the location of and an approach to death (hospital, intensive care unit or home with hospice care) for the future or if things do not go as hoped, rather than suggesting that death could be &ldquo;prevented.&rdquo;",
"   </p>",
"   <p>",
"    For some HF patients, a phase in which the patient is clearly nearing death may be characterized by progressive somnolence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decreased oral intake, and treatments can be withdrawn, except those that seem to provide comfort. Most families and patients will benefit from connection to spiritual, social, and bereavement services to negotiate the end of life. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Emotional, spiritual, psychological, and social support'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=see_link\">",
"     \"Ethical issues near the end of life\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF THE END OF LIFE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians managing patients with advanced HF must first optimize medical and other interventions for HF in an attempt to maximize function and well being. Collaboration between clinicians, experts in HF care, and those experts in end of life care should be ensured.",
"   </p>",
"   <p>",
"    Cognitive impairment, including executive dysfunction in advanced HF, makes it difficult for the patients to follow logical sequences of action. Thus, patients and their families benefit from very clear written directions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    regular telephone instructions, including specification of a weight above which they should take additional diuretics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Challenges to end of life care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge of symptom management in HF lags behind knowledge of how to impact other outcomes. In patients with New York Heart Association (NYHA) functional class III-IV HF, the two major classes of drugs that improve mortality (angiotensin converting enzyme inhibitors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angiotensin II receptor blockers, and beta blockers) also improve dyspnea, or a composite of HF symptoms, and the requirement for diuretics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'Pharmacologic therapy of HF'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link&amp;anchor=H2#H2\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\", section on 'Benefit of ace inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2680?source=see_link&amp;anchor=H25855302#H25855302\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\", section on 'Symptomatic benefit'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link&amp;anchor=H2#H2\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\", section on 'Clinical benefit'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The impact of interventions on specific symptoms was not evaluated in most large trials for patients with advanced HF. In addition, studies of palliative care interventions that included HF patients reported limited data on patient characteristics and the interventions utilized. The lack of clearly identified interventions for palliative care in HF, as well as variable end of life care provided in hospice for HF patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/28\">",
"     28",
"    </a>",
"    ], present significant barriers to initiating end of life care for HF patients.",
"   </p>",
"   <p>",
"    Provision of palliative care at the end of life for HF patients is further challenged by limitations in clinician expertise. Cardiologists and HF specialists with expertise in HF management may not have training in palliative care, while generalists, geriatricians, and other clinicians with expertise in hospice and palliative care often lack knowledge and expertise in HF management [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Cardiologists not versed in options for palliative care in their community might best set goals and identify an approach to care together with physicians with expertise palliative care.",
"   </p>",
"   <p>",
"    Limitations in delivery of care may also lead to suboptimal adherence to evidence-based therapies that could improve quality of life as well as survival. The majority of persons who care for HF patients are primary care clinicians, yet as a group these providers provide less evidence-based care, and may thus fail to optimally improve quality of life for patients with advanced HF, particularly elderly patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The effect of specialty care and disease management programs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37929?source=see_link\">",
"     \"Strategies to reduce hospitalizations in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Withdrawal of evidenced-based therapies may be appropriate during end-stage care for certain patients with persistent advanced HF, particularly those with hypotension or left ventricular systolic dysfunction with progressive low-output and hypotension. When these treatments are discontinued, a plan to manage symptoms should be enacted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Symptom management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of fatigue, dyspnea, pain, sleep disturbance, cognitive impairment, depression and anxiety, and anorexia or weight loss have been well documented in patients with advanced HF [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. Symptom burden accounts for much of worsened HF-related quality of life in HF patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/37\">",
"     37",
"    </a>",
"    ], and the spiritual well-being, depression symptoms and symptom burden scores of advanced HF patients parallels that of patients with advanced cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As in other chronic heart and serious illnesses, assessment of symptoms using a questionnaire or standardized interview will yield more symptoms than waiting for patients to volunteer symptoms. A general approach to symptom assessment at the end of life is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28490?source=see_link\">",
"     \"Overview of comprehensive patient assessment in palliative care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=see_link\">",
"     \"Approach to symptom assessment in palliative care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management should be aimed at optimizing HF treatment as well as addressing specific symptoms. Medications specifically targeting symptom relief, such as opioids for analgesia or relief of dyspnea are endorsed in current guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/3\">",
"     3",
"    </a>",
"    ]. Palliative therapies such as opioid medications may also improve exercise capacity with increase in peak oxygen consumption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Treatment of HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimization of HF therapy is a key component of advanced HF care, even after the presence of advanced persistent HF has been established and the major goal is palliation of symptoms. Some key components of HF treatment are highlighted here. Treatment of HF is discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4743?source=see_link\">",
"     \"Management of refractory heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Fluid overload should be reduced with diuretics (including loop diuretics, thiazides, and aldosterone antagonists, as indicated) and fluid and salt intake should be restricted, as tolerated. Modest stable elevations in the blood urea nitrogen and serum creatinine may be accepted, if necessary, and moderate hypotension may be allowed as tolerated to achieve the best possible reduction in congestion. Addition of an aldosterone-blocking agent such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    and aggressive treatment of sleep-disordered breathing often help to achieve best possible volume status. Consultation from a clinician expert in HF management is often beneficial.",
"   </p>",
"   <p>",
"    Assessment of patient weight may be the most effective noninvasive method for documenting volume status. Body weight can also be utilized to guide adjustment in medications by patients or their care providers. This monitoring and medication adjustment, called &ldquo;self-management&rdquo; also helps patients and their families maintain a sense of control over their illness even when HF is advanced. For accurate comparisons, daily measurements should use the same scale and should be performed at the same time, usually in the morning, prior to eating and after voiding. Weight comparisons may require adjustment for variations in food intake, particularly since appetite may be diminished. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Anorexia and cachexia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Angiotensin inhibition, angiotensin receptor blocking, beta blockers, and aldosterone antagonists both prolong survival and alleviate symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link&amp;anchor=H4#H4\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\", section on 'Severity of HF'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link&amp;anchor=H27#H27\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\", section on 'Class IV HF'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=see_link\">",
"     \"Use of aldosterone antagonists in heart failure\"",
"    </a>",
"    .) Heart failure contrasts with other diseases at the end of life in that these medications (initiated to prolong survival) palliate HF symptoms, and thus are not routinely abandoned in advanced disease.",
"   </p>",
"   <p>",
"    However, patients with advanced HF may not tolerate their previous doses of these medications. When patients become intolerant of HF medications due to hypotension, one strategy is to reduce the doses of &beta;-blockers and ACE inhibitors or ARBs to lower-tolerated doses. Another approach is to eliminate one class of medication, while maintaining others. Research has not provided the evidence to suggest which tactic is most effective or best tolerated, however HF experts generally agree that to provide palliation, it is important to continue some agent to block the neurohormonal abnormalities of the HF syndrome.",
"   </p>",
"   <p>",
"    Intravenous inotropes are effective palliative therapies for certain end-stage HF patients with systolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/39\">",
"     39",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    HF guidelines suggest that continuous intravenous infusion of a positive inotropic agent may be considered for palliation of symptoms in patients with refractory end-stage HF [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4743?source=see_link\">",
"     \"Management of refractory heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=see_link\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Fatigue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue is clearly associated with both the psychological and physical condition of patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/40\">",
"     40",
"    </a>",
"    ]. Fatigue may be due to decreased cardiac output, elevated neurohormones, deconditioning, sleep impairment, and depression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anxiety.",
"   </p>",
"   <p>",
"    Assessment and treatment of fatigue should be multifaceted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improving dietary compliance by restricting fluids and sodium intake results in reduced fatigue and edema [",
"      <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In HF patients with anemia, erythropoietin therapy may enhance exercise capacity [",
"      <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/42\">",
"       42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1705?source=see_link\">",
"       \"Impact of anemia in patients with heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Opioids and caffeine (and possibly other stimulants) may improve exertional fatigue [",
"      <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In chronic HF, selective thigh muscle strengthening improves fatigue [",
"      <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/45\">",
"       45",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approximately one-half of patients with advanced HF have sleep-disordered breathing (SDB). Both sleep apnea and Cheyne-Stokes respiration cause worsened exercise capacity. Optimization of medical management of heart failure is the primary therapy for patients whose HF is complicated by SDB, because it improves HF-related outcomes and may improve SDB. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=see_link\">",
"     \"Cheyne-Stokes breathing and obstructive sleep apnea in heart failure\"",
"    </a>",
"    .) For patients who have persistent SDB despite optimization of HF therapy, treatment of SDB has not been shown to improve HF-related mortality or hospitalization rates, although continuous positive airway pressure (CPAP) improves left ventricular function, daytime alertness and exercise capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/46\">",
"     46",
"    </a>",
"    ] and nocturnal oxygen may improve exercise capacity and neurohormonal status [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/47\">",
"     47",
"    </a>",
"    ]. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=see_link&amp;anchor=H8#H8\">",
"     \"Cheyne-Stokes breathing and obstructive sleep apnea in heart failure\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Dyspnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyspnea treatment has traditionally focused on reducing congestion with HF therapy, particularly loop diuretics. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Treatment of HF'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Nitrates also reduce left ventricular end diastolic pressure and are commonly prescribed to reduce dyspnea and improve exercise tolerance in patients with and without ischemic etiology of HF [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/45\">",
"     45",
"    </a>",
"    ]. Nitrate therapy may reduce dyspnea at night and with exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/4\">",
"     4",
"    </a>",
"    ]. The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    and a nitrate is reasonable in patients with persistent HF symptoms on an ACE inhibitor and beta blocker, while the evidence is less well established in patients who cannot tolerate an ACE inhibitor or ARB [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exercise training is recommended in patients with NYHA class II and III HF since it reduces dyspnea and improves endurance and quality of life. However, the role of exercise in patients with class IV HF has not yet been defined, although there is evidence that specific exercise to strengthen thigh muscles in advanced HF patients improves dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=see_link\">",
"     \"Cardiac rehabilitation in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Opioids reduce hypoxic ventilatory drive, act on opioid receptors in the lung, and may unload volume.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     Morphine",
"    </a>",
"    , dihydrocodeine, or diamorphine improve exercise tolerance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exercise-related dyspnea in patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/43,49,50\">",
"     43,49,50",
"    </a>",
"    ]. The use of opioid medications for dyspnea is not a FDA-approved indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain prevalence ranges from 40 to 75 percent in persons with advanced HF [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/36,51,52\">",
"     36,51,52",
"    </a>",
"    ], but the etiology and location of such pain remains to be elucidated [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/35\">",
"     35",
"    </a>",
"    ]. Clinicians should inquire about pain and develop strategies for management.",
"   </p>",
"   <p>",
"    Arthritis may be one of the main sources of pain in older persons with HF, but a major class of treatment for arthritis, the nonsteroidal antiinflammatory drugs (NSAIDs), are contraindicated in HF patients because they impair renal function, cause sodium and fluid retention, worsen HF and increase the risk of hospitalization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link&amp;anchor=H7#H7\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\", section on 'Heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Local treatments such as heat or cold therapy and physical therapy should be considered in a multidisciplinary approach to pain management. Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/23/30072?source=see_link\">",
"     topical salicylates",
"    </a>",
"    may also be considered, although limited data are available on their use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=see_link\">",
"     \"Nonpharmacologic therapy of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9687?source=see_link&amp;anchor=H34171222#H34171222\">",
"     \"Investigational approaches to the pharmacologic therapy of osteoarthritis\", section on 'Counter-irritants and rubefacients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Low-dose opioids are effective in reducing pain without significant toxicity in older persons with arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/53\">",
"     53",
"    </a>",
"    ] and may be considered in patients with advanced HF when other therapies are not adequate. Opioids with active renal-excreted metabolites (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ) should not be used chronically because of the prevalence of renal dysfunction in advanced HF patients, although other opioids without active metabolites (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    ) or with GI excretion (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    ) may be appropriate for chronic use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=see_link\">",
"     \"Pharmacologic therapy of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Anorexia and cachexia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorexia, weight loss, and protein malnutrition are common features of advanced HF and are related to the associated neurohormonal and cytokine abnormalities, and to the skeletal myopathy that accompanies the HF syndrome. Anorexia may also result from volume overload, particularly when intestinal edema and hepatic congestion are present. Treatment should include optimizing HF medical management including volume status and ACE inhibitor therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since changes in weight may reflect changes in food intake and body size as well as fluid balance, weight targets for diuretic use may require adjustment over time.",
"   </p>",
"   <p>",
"    Issues related to stopping nutrition and hydration at the end of life are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/34/13866?source=see_link\">",
"     \"End of life care: Stopping nutrition and hydration\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Emotional, spiritual, psychological, and social support",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of HF on quality of life for both patient and family is complex and extends beyond physical symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/55\">",
"     55",
"    </a>",
"    ]. The loss of physical and social function is significant. HF patients are frightened of dying, worried about burdening families, and experience hopelessness, isolation, disability and uncertainty regarding their course [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29769?source=see_link\">",
"     \"Psychosocial issues at the end of life\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients benefit from active-behavioral coping style including strategies to constructively control their HF [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/58\">",
"     58",
"    </a>",
"    ]. Approaches to spiritual issues and anticipatory grief, such as used in other advanced illnesses, are appropriate in HF [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/55,59\">",
"     55,59",
"    </a>",
"    ]. At minimum, clinicians should screen for spiritual concerns and sources of support [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/60\">",
"     60",
"    </a>",
"    ] and acknowledge patients' losses and sources of grief. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41208?source=see_link\">",
"     \"Religion, spirituality, and end of life care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Depression in advanced HF is associated with poorer health status, more limitation in physical function, breathlessness and fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/61\">",
"     61",
"    </a>",
"    ]. Advanced HF patients should be screened for depression and treatment should be initiated with supportive counseling [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/62\">",
"     62",
"    </a>",
"    ]. Limited data are available on pharmacologic, cognitive, and exercise therapy for depression in HF patients. A small controlled trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    for patients with depression and HF resulted in improved depression and psychological aspects of quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/63\">",
"     63",
"    </a>",
"    ], yet a larger trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    at low doses did not benefit depressed HF patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/64\">",
"     64",
"    </a>",
"    ]. Some patients will benefit from pharmacological therapy with selective serotonin reuptake inhibitors (SSRIs), psychostimulants such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    or tricyclic antidepressants such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    , which have less significant anticholinergic effects such as orthostatic hypotension than other tricyclics [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/65\">",
"     65",
"    </a>",
"    ]. Medication side effects to be monitored include QT prolongation with tricyclic antidepressants and hyponatremia (particularly in older patients) with SSRIs [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38858?source=see_link\">",
"     \"Assessment and management of depression in palliative care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13711359\">",
"    <span class=\"h2\">",
"     ICD deactivation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with end-stage HF who have implantable cardioverter defibrillators (ICDs) should be provided with information concerning the potential benefits and burdens of ICD therapy to enable an informed decision on whether to deactivate the device [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/2-4,24,67\">",
"     2-4,24,67",
"    </a>",
"    ]. A 2010 Heart Rhythm Society expert consensus statement discusses ethical and legal issues and management of ICDs and other electrical devices in patients nearing the end of life [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/24\">",
"     24",
"    </a>",
"    ]. A sample ICD deactivation policy including ethical rationale, process of informed consent, and process for deactivation has been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/67\">",
"     67",
"    </a>",
"    ]. Turning off the defibrillator function should be presented as a simple step which may be consistent with the goal of preserving quality of life during the dying process. The ICD shocking function is deactivated by reprogramming the device, which can be performed in a clinic, hospice, or home setting (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39672?source=see_link&amp;anchor=H13#H13\">",
"     \"Implantable cardioverter-defibrillators: Patient follow-up\", section on 'Discontinuation of ICD therapy'",
"    </a>",
"    ). A decision to deactivate any accompanying pacemaker should be made separately as this involves consideration of the indications for pacemaker therapy. &nbsp;",
"   </p>",
"   <p>",
"    If the decision is made to leave an ICD active, emergent deactivation to stop repeated shocks can be accomplished for most devices (depending upon the brand and model) by placing a magnet designed for pacemakers over the ICD. While the magnet is in place, the ICD will not sense and will not deliver treatments. For most devices, ICD therapy is suspended only while the magnet is in place but some models are reprogrammed by the magnet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hospice care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospice care may serve as a resource for end-of-life care for patients and their families in the home, hospital setting, or special hospice unit. Hospice teams provide multidisciplinary coordinated care for bereavement, spiritual, psychological and social issues in addition to medical and nursing care. The principles and general use of hospice care are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32008?source=see_link\">",
"     \"Hospice: Philosophy of care and appropriate utilization in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Medicare hospice benefit requires physicians to certify that patients have a life expectancy of six months or less if the disease runs its likely course. Difficulties identifying when a HF patient meets this criterion may limit hospice referrals. Current hospice referral guidelines for \"end-stage cardiac disease\" include New York Heart Association (NYHA) Class IV (symptomatic at rest), or Class III (symptomatic with activities of daily living) with other comorbidities, for whom \"maximal\" therapies were tried, not tolerated or refused [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/68\">",
"     68",
"    </a>",
"    ]. Relying on NYHA classification probably includes patients with longer than six-month life expectancy, and prognosis needs to be individually assessed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation of the patient with heart failure or cardiomyopathy\", section on 'Definition and classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hospice use is substantially lower in HF patients than in those with advanced cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/69\">",
"     69",
"    </a>",
"    ]. However, use of hospice among HF patients appears to be increasing. In a study of over 200,000 Medicare beneficiaries with HF, hospice use in the last six months of life increased from 19 percent in 2000 to 40 percent in 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/70\">",
"     70",
"    </a>",
"    ]. Referral to hospice after hospitalization for acute decompensated HF varies geographically and by hospital characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/71\">",
"     71",
"    </a>",
"    ]. Patients referred to hospice were less likely than other HF patients to have received evidence-based therapies prior to discharge, although this difference may reflect greater illness severity rather than differences in quality of care [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians and patients with advanced HF may misunderstand the role of hospice care because of misconceptions about prognosis or about hospice (such as that it is limited to patients with cancer or that it would require abandonment of appropriate HF therapy).",
"   </p>",
"   <p>",
"    Hospices generally provide oral medications for HF and for symptom management. Few hospices provide more complex treatments, such as intravenous inotrope and continuous positive airway pressure (CPAP), or have staff education, specific care plans for HF care, or protocols for management of implantable defibrillators and other devices [",
"    <a class=\"abstract\" href=\"UTD.htm?2/37/2650/abstract/32\">",
"     32",
"    </a>",
"    ]. Larger hospice agencies are more likely to provide complex or expensive therapies.",
"   </p>",
"   <p>",
"    Clinicians should continue to participate in patient management after the patient enrolls in hospice. Ongoing education of hospice staff about HF management is critical, and meticulous management of fluid status should be continued to maximize quality of life as patients approach death. Clinicians caring for HF patients likely to receive intravenous inotropes for palliative care should build relationships with hospice agencies that are equipped to provide them.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=see_link\">",
"       \"Patient information: Medical care during advanced illness (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/61/25554?source=see_link\">",
"       \"Patient information: Advance directives (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3780844\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Palliative care should be provided throughout the course of HF care, based upon patient and family needs, rather than upon an estimate of prognosis.",
"     </li>",
"     <li>",
"      Communication with HF patients and their families about their preferences for care and the potential life-limiting nature of HF early in the course of illness will facilitate later conversations when the patients&rsquo; disease status worsens or they approach the end of life. The majority of HF patients prefer honest communication about their illness from doctors.",
"     </li>",
"     <li>",
"      Meticulous management of HF and associated syndromes, such as sleep-disordered breathing, are a critical component of palliation of symptoms in HF patients.",
"     </li>",
"     <li>",
"      Palliative care that is multidisciplinary is indicated to address the broad physical and psychological symptom burden in advanced HF. Some data support specific treatments for symptoms, although extrapolation from chronic HF data is necessary because few data inform care for advanced HF patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108826805\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. Stephen S. Gottlieb for his contributions as a Section Editor to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/1\">",
"      Setoguchi S, Stevenson LW. Hospitalizations in patients with heart failure: who and why. J Am Coll Cardiol 2009; 54:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/2\">",
"      Goodlin SJ, Hauptman PJ, Arnold R, et al. Consensus statement: Palliative and supportive care in advanced heart failure. J Card Fail 2004; 10:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/3\">",
"      Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/4\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/5\">",
"      Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/6\">",
"      Lee CS, Moser DK, Lennie TA, Riegel B. Event-free survival in adults with heart failure who engage in self-care management. Heart Lung 2011; 40:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/7\">",
"      Goldberg LR, Jessup M. A time to be born and a time to die. Circulation 2007; 116:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/8\">",
"      Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001; 345:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/9\">",
"      Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J 2007; 154:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/10\">",
"      Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003; 290:2581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/11\">",
"      Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006; 113:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/12\">",
"      Ko DT, Alter DA, Austin PC, et al. Life expectancy after an index hospitalization for patients with heart failure: a population-based study. Am Heart J 2008; 155:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/13\">",
"      Mozaffarian D, Anker SD, Anand I, et al. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation 2007; 116:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/14\">",
"      Ansari M, Alexander M, Tutar A, et al. Cardiology participation improves outcomes in patients with new-onset heart failure in the outpatient setting. J Am Coll Cardiol 2003; 41:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/15\">",
"      Jong P, Gong Y, Liu PP, et al. Care and outcomes of patients newly hospitalized for heart failure in the community treated by cardiologists compared with other specialists. Circulation 2003; 108:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/16\">",
"      Kfoury AG, French TK, Horne BD, et al. Incremental survival benefit with adherence to standardized heart failure core measures: a performance evaluation study of 2958 patients. J Card Fail 2008; 14:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/17\">",
"      Teuteberg JJ, Lewis EF, Nohria A, et al. Characteristics of patients who die with heart failure and a low ejection fraction in the new millennium. J Card Fail 2006; 12:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/18\">",
"      Derfler MC, Jacob M, Wolf RE, et al. Mode of death from congestive heart failure: implications for clinical management. Am J Geriatr Cardiol 2004; 13:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/19\">",
"      Carson P, Anand I, O'Connor C, et al. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005; 46:2329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/20\">",
"      Luu M, Stevenson WG, Stevenson LW, et al. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 1989; 80:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/21\">",
"      Teno JM, Weitzen S, Fennell ML, Mor V. Dying trajectory in the last year of life: does cancer trajectory fit other diseases? J Palliat Med 2001; 4:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/22\">",
"      Hopp FP, Thornton N, Martin L. The lived experience of heart failure at the end of life: a systematic literature review. Health Soc Work 2010; 35:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/23\">",
"      Strachan PH, Ross H, Rocker GM, et al. Mind the gap: Opportunities for improving end-of-life care for patients with advanced heart failure. Can J Cardiol 2009; 25:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/24\">",
"      Lampert R, Hayes DL, Annas GJ, et al. HRS Expert Consensus Statement on the Management of Cardiovascular Implantable Electronic Devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy. Heart Rhythm 2010; 7:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/25\">",
"      Goodlin SJ, Quill TE, Arnold RM. Communication and decision-making about prognosis in heart failure care. J Card Fail 2008; 14:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/26\">",
"      Allen LA, Yager JE, Funk MJ, et al. Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure. JAMA 2008; 299:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/27\">",
"      Back AL, Arnold RM, Quill TE. Hope for the best, and prepare for the worst. Ann Intern Med 2003; 138:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/28\">",
"      Goodlin SJ, Kutner JS, Connor SR, et al. Hospice care for heart failure patients. J Pain Symptom Manage 2005; 29:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/29\">",
"      Hauptman PJ, Swindle J, Hussain Z, et al. Physician attitudes toward end-stage heart failure: a national survey. Am J Med 2008; 121:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/30\">",
"      Goodlin SJ, Trupp R, Bernhardt P, et al. Development and evaluation of the \"Advanced Heart Failure Clinical Competence Survey\": a tool to assess knowledge of heart failure care and self-assessed competence. Patient Educ Couns 2007; 67:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/31\">",
"      Kim DH, Hunt SA. Heart failure management: caregiver versus care plan. Circulation 2003; 108:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/32\">",
"      Komajda M, Hanon O, Hochadel M, et al. Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I. Eur Heart J 2007; 28:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/33\">",
"      Dracup K, Walden JA, Stevenson LW, Brecht ML. Quality of life in patients with advanced heart failure. J Heart Lung Transplant 1992; 11:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/34\">",
"      Krum H, Gilbert RE. Demographics and concomitant disorders in heart failure. Lancet 2003; 362:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/35\">",
"      Goodlin SJ, Wingate S, Pressler SJ, et al. Investigating pain in heart failure patients: rationale and design of the Pain Assessment, Incidence &amp; Nature in Heart Failure (PAIN-HF) study. J Card Fail 2008; 14:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/36\">",
"      Walke LM, Gallo WT, Tinetti ME, Fried TR. The burden of symptoms among community-dwelling older persons with advanced chronic disease. Arch Intern Med 2004; 164:2321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/37\">",
"      Zambroski CH, Moser DK, Bhat G, Ziegler C. Impact of symptom prevalence and symptom burden on quality of life in patients with heart failure. Eur J Cardiovasc Nurs 2005; 4:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/38\">",
"      Bekelman DB, Rumsfeld JS, Havranek EP, et al. Symptom burden, depression, and spiritual well-being: a comparison of heart failure and advanced cancer patients. J Gen Intern Med 2009; 24:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/39\">",
"      Hershberger RE, Nauman D, Walker TL, et al. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. J Card Fail 2003; 9:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/40\">",
"      Evangelista LS, Moser DK, Westlake C, et al. Correlates of fatigue in patients with heart failure. Prog Cardiovasc Nurs 2008; 23:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/41\">",
"      Col&iacute;n Ram&iacute;rez E, Castillo Mart&iacute;nez L, Orea Tejeda A, et al. Effects of a nutritional intervention on body composition, clinical status, and quality of life in patients with heart failure. Nutrition 2004; 20:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/42\">",
"      Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003; 107:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/43\">",
"      Williams SG, Wright DJ, Marshall P, et al. Safety and potential benefits of low dose diamorphine during exercise in patients with chronic heart failure. Heart 2003; 89:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/44\">",
"      Notarius CF, Morris B, Floras JS. Caffeine prolongs exercise duration in heart failure. J Card Fail 2006; 12:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/45\">",
"      Bitar F, Akhter MW, Khan S, et al. Survey of the use of organic nitrates for the treatment of chronic congestive heart failure in the United States. Am J Cardiol 2004; 94:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/46\">",
"      Bradley TD, Logan AG, Kimoff RJ, et al. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 2005; 353:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/47\">",
"      Arzt M, Bradley TD. Treatment of sleep apnea in heart failure. Am J Respir Crit Care Med 2006; 173:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/48\">",
"      Beniaminovitz A, Lang CC, LaManca J, Mancini DM. Selective low-level leg muscle training alleviates dyspnea in patients with heart failure. J Am Coll Cardiol 2002; 40:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/49\">",
"      Johnson MJ, McDonagh TA, Harkness A, et al. Morphine for the relief of breathlessness in patients with chronic heart failure--a pilot study. Eur J Heart Fail 2002; 4:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/50\">",
"      Chua TP, Harrington D, Ponikowski P, et al. Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 1997; 29:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/51\">",
"      Levenson JW, McCarthy EP, Lynn J, et al. The last six months of life for patients with congestive heart failure. J Am Geriatr Soc 2000; 48:S101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/52\">",
"      Weiss SC, Emanuel LL, Fairclough DL, Emanuel EJ. Understanding the experience of pain in terminally ill patients. Lancet 2001; 357:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/53\">",
"      Goldberg SH, Von Feldt JM, Lonner JH. Pharmacologic therapy for osteoarthritis. Am J Orthop (Belle Mead NJ) 2002; 31:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/54\">",
"      Anker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003; 361:1077.",
"     </a>",
"    </li>",
"    <li>",
"     Gillilan, R, Puchalski, C. Spiritual issues in heart failure. In: Supportive Care in Heart Failure, Beattie, J, Goodlin, S (Eds), Oxford University Press, Oxford 2008. p.299.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/56\">",
"      Murray SA, Kendall M, Boyd K, et al. Exploring the spiritual needs of people dying of lung cancer or heart failure: a prospective qualitative interview study of patients and their carers. Palliat Med 2004; 18:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/57\">",
"      Horne G, Payne S. Removing the boundaries: palliative care for patients with heart failure. Palliat Med 2004; 18:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/58\">",
"      Doering LV, Dracup K, Caldwell MA, et al. Is coping style linked to emotional states in heart failure patients? J Card Fail 2004; 10:344.",
"     </a>",
"    </li>",
"    <li>",
"     Cowan DS, Hatfield  K. Support in Heart Failure Care. In: Supportive Care in Heart Failure, Beattie J, Goodlin SJ (Eds), Oxford University Press, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/60\">",
"      Puchalski C, Romer AL. Taking a spiritual history allows clinicians to understand patients more fully. J Palliat Med 2000; 3:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/61\">",
"      Sullivan M, Levy WC, Russo JE, Spertus JA. Depression and health status in patients with advanced heart failure: a prospective study in tertiary care. J Card Fail 2004; 10:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/62\">",
"      Goodlin SJ. Sadness in heart failure: what is a clinician to do? J Am Coll Cardiol 2010; 56:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/63\">",
"      Gottlieb SS, Kop WJ, Thomas SA, et al. A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure. Am Heart J 2007; 153:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/64\">",
"      O'Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol 2010; 56:692.",
"     </a>",
"    </li>",
"    <li>",
"     Bekelman DB, Sullivan M. Depression and Anxiety in Patients with Chronic Heart Failure. In: Supportive Care in Heart Failure, Beattie J, Goodlin SJ (Eds), Oxford University Press, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/66\">",
"      Kirby D, Ames D. Hyponatraemia and selective serotonin re-uptake inhibitors in elderly patients. Int J Geriatr Psychiatry 2001; 16:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/67\">",
"      Goldstein N, Carlson M, Livote E, Kutner JS. Brief communication: Management of implantable cardioverter-defibrillators in hospice: A nationwide survey. Ann Intern Med 2010; 152:296.",
"     </a>",
"    </li>",
"    <li>",
"     Stuart, B, Alexander, C, Arenella, C, et al for Standards and Accreditation Committee, Medical Guidelines Task Force. Medical Guidelines for Determining Prognosis in Selected Non-Cancer Diseases. Arlington, VA: National Hospice Organization, 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/69\">",
"      Setoguchi S, Glynn RJ, Stedman M, et al. Hospice, opiates, and acute care service use among the elderly before death from heart failure or cancer. Am Heart J 2010; 160:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/70\">",
"      Unroe KT, Greiner MA, Hernandez AF, et al. Resource use in the last 6 months of life among medicare beneficiaries with heart failure, 2000-2007. Arch Intern Med 2011; 171:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/37/2650/abstract/71\">",
"      Hauptman PJ, Goodlin SJ, Lopatin M, et al. Characteristics of patients hospitalized with acute decompensated heart failure who are referred for hospice care. Arch Intern Med 2007; 167:1990.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3511 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-77.94.48.4-CE85A84A2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_37_2650=[""].join("\n");
var outline_f2_37_2650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3780844\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      IDENTIFICATION OF END-STAGE HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3780922\">",
"      Estimation of prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3781077\">",
"      COURSE TO DEATH IN HF PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      COMMUNICATION WITH THE PATIENT AND FAMILY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MANAGEMENT OF THE END OF LIFE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Challenges to end of life care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Symptom management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Treatment of HF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Fatigue",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Dyspnea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Anorexia and cachexia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Emotional, spiritual, psychological, and social support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13711359\">",
"      ICD deactivation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hospice care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3780844\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H108826805\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3511\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3511|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?1/38/1637\" title=\"algorithm 1\">",
"      Stages evolution HF and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3511|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/22/15724\" title=\"table 1\">",
"      ACC AHA Rx refractory HF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2680?source=related_link\">",
"      Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=related_link\">",
"      Approach to symptom assessment in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38858?source=related_link\">",
"      Assessment and management of depression in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=related_link\">",
"      Cardiac rehabilitation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=related_link\">",
"      Cheyne-Stokes breathing and obstructive sleep apnea in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/34/13866?source=related_link\">",
"      End of life care: Stopping nutrition and hydration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=related_link\">",
"      Ethical issues near the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=related_link\">",
"      Evaluation of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=related_link\">",
"      Evaluation of the patient with heart failure or cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32008?source=related_link\">",
"      Hospice: Philosophy of care and appropriate utilization in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1705?source=related_link\">",
"      Impact of anemia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39672?source=related_link\">",
"      Implantable cardioverter-defibrillators: Patient follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=related_link\">",
"      Indications and contraindications for cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=related_link\">",
"      Inotropic agents in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37785?source=related_link\">",
"      Intermediate- and long-term mechanical cardiac support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9687?source=related_link\">",
"      Investigational approaches to the pharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4743?source=related_link\">",
"      Management of refractory heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=related_link\">",
"      Nonpharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28490?source=related_link\">",
"      Overview of comprehensive patient assessment in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/61/25554?source=related_link\">",
"      Patient information: Advance directives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=related_link\">",
"      Patient information: Medical care during advanced illness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=related_link\">",
"      Pharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=related_link\">",
"      Predictors of survival in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4058?source=related_link\">",
"      Prognosis of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29769?source=related_link\">",
"      Psychosocial issues at the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41208?source=related_link\">",
"      Religion, spirituality, and end of life care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37929?source=related_link\">",
"      Strategies to reduce hospitalizations in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35143?source=related_link\">",
"      Surgical management of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=related_link\">",
"      Ventricular arrhythmias in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_37_2651="Clues for anaerobic infection";
var content_f2_37_2651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clues to probability of anaerobic bacteria at infection site",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Infection adjacent to surfaces that normally harbor anaerobes as normal flora",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abscess formation or tissue necrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Putrid odor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gas formation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gram stain of exudate showing polymicrobial flora or organisms with morphologic features of anaerobes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Classic features of histotoxic clostridial syndromes:",
"tetanus, botulism, C. perfringens food poisoning, gas gangrene, C.",
"difficile-induced diarrhea or colitis, enteritis necroticans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infections that, by prior experience, usually involve anaerobic bacteria",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_37_2651=[""].join("\n");
var outline_f2_37_2651=null;
var title_f2_37_2652="Symptoms RTH";
var content_f2_37_2652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features: frequency of symptoms and signs in RTH",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Findings",
"      </td>",
"      <td class=\"subtitle1\">",
"       Frequency, percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thyroid gland",
"      </td>",
"      <td>",
"       Goiter",
"      </td>",
"      <td>",
"       66-95",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Heart",
"      </td>",
"      <td>",
"       Tachycardia",
"      </td>",
"      <td>",
"       33-75",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       Nervous system",
"      </td>",
"      <td>",
"       Emotional disturbances",
"      </td>",
"      <td>",
"       60",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hyperkinetic behavior",
"      </td>",
"      <td>",
"       33-68",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Attention deficit hyperactivity disorder",
"      </td>",
"      <td>",
"       40-60",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Learning disability",
"      </td>",
"      <td>",
"       30",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mental retardation (IQ &lt;70)",
"      </td>",
"      <td>",
"       4-16",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hearing loss (sensorineural)",
"      </td>",
"      <td>",
"       10-22",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Growth and development",
"      </td>",
"      <td>",
"       Short stature (&lt;5 percent)",
"      </td>",
"      <td>",
"       18-25",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Delayed bone age &gt;2 SD",
"      </td>",
"      <td>",
"       29-47",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Low body mass index (in children)",
"      </td>",
"      <td>",
"       33",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Recurrent ear and throat infections",
"      </td>",
"      <td>",
"       55",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IQ: intellectual quotient.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      Refetoff, S, Weiss, RE, Usala, SJ. The syndromes of resistance to thyroid hormone. Endocr Rev 1993; 14:348.",
"      <br>",
"       Beck-Peccoz, P, Chatterjee, VK. The variable clinical phenotype in thyroid hormone resistance syndrome. Thyroid 1994; 4:225.",
"       <br>",
"        Brucker-Davis, F, Skarulis, MC, Grace, MB, et al. Genetic and clinical features of 42 kindreds with resistance to thyroid hormone. The National Institutes of Health Prospective Study. Ann Intern Med 1995; 123:572.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_37_2652=[""].join("\n");
var outline_f2_37_2652=null;
var title_f2_37_2653="Drug and toxin related pulmonary edema or pneumonitis";
var content_f2_37_2653=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Agents associated with noncardiogenic pulmonary edema",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Irritant gases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ammonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Chlorine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Hydrogen sulfide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Nitrogen oxides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Phosgene",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Smoke",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Sulfur dioxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Metal oxides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Acid and alkaline gases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Aldehydes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Isocyanates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Polymers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Volatile inhalants (hydrocarbons)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Gasoline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Kerosene",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Butane",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Beryllium",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Opiates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Heroin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Methadone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Sedative-hypnotics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ethchlorvynol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Cellular asphyxiants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cyanide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Carbon monoxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Salicylates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Organophosphates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phencyclidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Paraquat",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ethylene glycol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Heavy metals",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sympathomimetics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Beta blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Calcium-channel blockers",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Any agent that causes prolonged hypoxia or hypotension may result in the acute respiratory distress syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_37_2653=[""].join("\n");
var outline_f2_37_2653=null;
var title_f2_37_2654="Contents: Insect allergy";
var content_f2_37_2654=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?43/1/44061\">",
"       Allergy and Immunology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Insect allergy",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Insect allergy",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Insect bites",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/16/24839\">",
"           Approach to the patient with a suspected spider bite: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/23/39286\">",
"           Bedbugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/43/24248\">",
"           Bites of recluse spiders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/31/25081\">",
"           Bites of widow spiders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/35/28216\">",
"           Insect bites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/50/41766\">",
"           Large local reactions to mosquito bites (Skeeter Syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/1/43031\">",
"           Prevention of arthropod and insect bites: Repellents and other measures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/48/36615\">",
"           Reactions to bites from kissing bugs (Triatoma)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Insect stings",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/1/12313\">",
"           Bee, yellow jacket, wasp, and other Hymenoptera stings: Reaction types and acute management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/22/6502\">",
"           Bees, yellow jackets, hornets, and wasps: Avoidance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/3/9271\">",
"           Bees, yellow jackets, hornets, and wasps: Biology and identification",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/30/14824\">",
"           Diagnosis of Hymenoptera venom allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/36/7752\">",
"           Entomology and control of imported fire ants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/59/13239\">",
"           Hymenoptera venom immunotherapy: Determining duration of therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/34/16936\">",
"           Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/5/39000\">",
"           Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/51/7994\">",
"           Stings of imported fire ants: Clinical manifestations, diagnosis, and treatment",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-68D89F9E18-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f2_37_2654=[""].join("\n");
var outline_f2_37_2654=null;
var title_f2_37_2655="Osmotic pressure and body water";
var content_f2_37_2655=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Osmolality and water distribution",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 348px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Osmolality of the body fluids and the distribution of the total body water between the intracellular and extracellular fluids in the (a) control state and after the addition of (b) NaCl, (c) H2O, or (d) isotonic NaCl and H2O to the extracellular fluid. For simplicity, it is assumed that Na+ salts account for all the extracellular osmoles and K+ salts for all the intracellular osmoles. See text for details.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Earley, LE, Clinical Disorders of Fluid and Electrolyte Metabolism, 2d ed, Maxwell, MH, Kleeman, CR (Eds), McGraw Hill, New York, 1972.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_37_2655=[""].join("\n");
var outline_f2_37_2655=null;
